US20110160080A1 - Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis - Google Patents

Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis Download PDF

Info

Publication number
US20110160080A1
US20110160080A1 US12/991,685 US99168509A US2011160080A1 US 20110160080 A1 US20110160080 A1 US 20110160080A1 US 99168509 A US99168509 A US 99168509A US 2011160080 A1 US2011160080 A1 US 2011160080A1
Authority
US
United States
Prior art keywords
protein
skin
melanoma
subject
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/991,685
Other languages
English (en)
Inventor
Sherman H. Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dermtech International
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US12/991,685 priority Critical patent/US20110160080A1/en
Assigned to DERMTECH INTERNATIONAL reassignment DERMTECH INTERNATIONAL ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHANG, SHERMAN H.
Publication of US20110160080A1 publication Critical patent/US20110160080A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Definitions

  • the invention relates generally to methods of characterizing pigmented skin lesions suspected of being melanomas using primarily non-invasive skin sampling.
  • Melanoma is a serious form of skin cancer in humans. It arises from the pigment cells (melanocytes), usually in the skin. The incidence of melanoma is increasing at the fastest rate of all cancers in the United States with a lifetime risk of 1 in 68. Although melanoma accounts for only 4% of all dermatologic cancers, it is responsible for 80% of all deaths from skin cancers. It has long been realized that recognition and diagnosis of melanoma, when it is early stage disease, is key to its cure.
  • Stage 1V the prognosis is dismal, with only 7-9% of patients surviving 5 years, with the median survival time being 8-9 months.
  • the long-term “cure” rate for Stage 1V melanoma is only 1-2%.
  • ELM epiluminescence microscopy
  • the present invention is based, in part, on the discovery that analysis of nucleic acid molecules or of protein expression products of nucleic acid molecules from specific genes can be used to characterize skin lesions in a subject.
  • the method provides valuable genetic information based on DNA, messenger RNA, or protein expression products obtained therefrom, for example.
  • the method involves use of a non-invasive approach for recovering nucleic acids such as DNA or messenger RNA or proteins from the surface of skin via a tape stripping procedure that permits a direct quantitative and qualitative assessment of biomarkers.
  • nucleic acids such as DNA or messenger RNA or proteins
  • the non-invasive method provides information regarding cells of the outermost layers of the skin that may not be obtained using biopsy samples.
  • the non-invasive method is far less traumatic than a biopsy.
  • the non-invasive method is used to capture cells on pigmented skin lesions that are suspected of being melanomas.
  • Nucleic acid molecules obtained from skin cells captured by the non-invasive method are analyzed in order to diagnose the nature of the lesion (e.g., malignant melanoma).
  • a nucleic acid molecule is amplified prior to analysis. Secondary outcomes could include tests for diagnosis and prognosis of a variety of pigmented skin lesions and even to predict a therapeutic regimen.
  • the skin cells are lysed to extract one or more proteins, which are then quantitated to diagnose the nature of the lesion. It should be understood that the methods of the invention are not limited to non-invasive techniques for obtaining skin samples.
  • non-invasive tape stripping is an illustrative example for obtaining a skin sample.
  • the methods involve detection of one or more mutations in the nucleic acid sequence of the nucleic acid molecule obtained from the skin.
  • mutations may be a substitution, a deletion, and/or an insertion of the nucleic acid sequence that results in a diseased state in the subject from which the skin sample is obtained.
  • the nucleic acid molecule analyzed is listed in Tables 10-12 and 15. In another embodiment, the method further includes analyzing one or more nucleic acid molecules listed Tables 1-8.
  • the gene analyzed is any one or more of interferon regulatory factor 6, claudin 23, melan-A, osteopetrosis associated transmembrane protein 1, RAS-like family 11 member B, actinin alpha 4, transmembrane protein 68, Glycine-rich protein (GRP3S), Transcription factor 4, hypothetical protein FLJ20489, cytochrome c somatic, transcription factor 4, Forkhead box P1, transducer of ERBB2-2, glutaminyl-peptide cyclotransferase (glutaminyl cyclase), hypothetical protein FLJ10770, selenophosphate synthetase 2, embryonal Fyn-associated substrate, Kruppel-like factor 8, Discs large homolog 5 (Drosophila), regulator of G-protein signalling 10, ADP-
  • a method for characterizing and/or diagnosing melanoma in a subject including obtaining a nucleic acid molecule or protein by biopsy of a skin lesion on the subject, and analyzing the nucleic acid molecule to distinguish melanoma from dysplastic nevi and/or normal pigmented skin in the subject.
  • at least one nucleic acid molecule whose expression is informative of melanoma is detected in the epidermal sample.
  • expression of one or more of the genes listed in Tables 1-8, 10-12, 15, or a combination thereof is detected in the epidermal sample to characterize the melanoma.
  • the gene is any one or more of interferon regulatory factor 6, claudin 23, melan-A, osteopetrosis associated transmembrane protein 1, RAS-like family 11 member B, actinin alpha 4, transmembrane protein 68, Glycine-rich protein (GRP3S), Transcription factor 4, hypothetical protein FLJ20489, cytochrome c somatic, transcription factor 4, Forkhead box P1, transducer of ERBB2-2, glutaminyl-peptide cyclotransferase (glutaminyl cyclase), hypothetical protein FLJ10770, selenophosphate synthetase 2, embryonal Fyn-associated substrate, Kruppel-like factor 8, Discs large homolog 5 (Drosophila), regulator of G-protein signalling 10, ADP-ribosylation factor related protein 2, TIMP metallopeptidase inhibitor 2,5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP
  • the non-invasive methods of the invention involve applying an adhesive tape to a target area of skin in a manner sufficient to isolate a sample adhering to the adhesive tape, wherein the sample includes nucleic acid molecules or proteins. Typically, at least one nucleic acid molecule or protein whose expression is informative of melanoma is detected in the sample.
  • the method of characterizing skin using tape stripping has a number of applications, such as the following: (i) disease classification/subclassification; (ii) monitoring disease severity and progression; (iii) monitoring treatment efficacy; and (iv) prediction of a particular treatment regimen.
  • All of these applications which themselves represent embodiments disclosed herein, preferably use non-invasive sampling to recover information that is otherwise difficult or impractical to recover (e.g., through the use of biopsies).
  • the information may be contained in the DNA, protein, or RNA of skin cells close to the surface of the skin.
  • expression of one or more of the genes listed in Tables 1-8, 10-12, 15, or a combination thereof is detected in the sample to characterize the sample.
  • This exemplary method is particularly useful for distinguishing melanoma from dysplastic nevi and/or normal pigmented skin.
  • expression of one or more of the genes listed in Table 12 or 15 is detected in the sample to characterize the sample.
  • a method for distinguishing solar lentigines from dysplastic nevi and/or basal cell carcinoma and/or normal pigmented skin in a subject including applying an adhesive tape to a target area of skin in a manner sufficient to isolate a sample adhering to the adhesive tape, wherein the sample includes nucleic acid molecules. At least one nucleic acid molecule whose expression is informative of solar lentigo is detected in the sample. In one embodiment, expression of one or more of the genes listed in Tables 10-12, 15, or a combination thereof, is detected in the sample to characterize the melanoma. In another embodiment, expression of one or more of the genes listed in Table 12 or 15 is detected in the sample to characterize the solar lentigo.
  • non-polar, pliable, adhesive tapes especially pliable tapes with rubber adhesive
  • pliable tapes with rubber adhesive are more effective than other types of adhesive tapes.
  • pliable tapes with rubber adhesives as few as 10 or less tape strippings and in certain examples as few as 4 or even 1 tape stripping can be used to isolate and/or detect nucleic acid molecules from the epidermal layer of the skin.
  • the methods of the invention provide for characterization of a skin lesion in situ, including application of a detectably labeled probe directly to a skin lesion for visual analysis. At least one nucleic acid molecule whose expression is informative of melanoma or dysplastic nevi or normal skin is detected on the skin lesion or surrounding margin or tissue using a specific probe. In one example, expression of one or more of the genes listed in Tables 1-8, 10-12, 15, or a combination thereof, is detected on the skin lesion or surrounding margin or tissue to characterize the melanoma. In one embodiment, expression of one or more of the genes listed in Tables 10-12 or 15 is detected in the sample to characterize the melanoma.
  • Also provided herein is a method for diagnosing a disease state by establishing a gene expression pattern of a target area suspected of being melanoma on the skin of a subject and comparing the subject's gene expression profile to a reference gene expression profile obtained from a corresponding normal skin sample.
  • the target area of the skin simultaneously expresses a plurality of genes at the protein level that are markers for melanoma.
  • the genes are listed in Tables 1-8, 10-12, 15, or any combination thereof.
  • the genes are listed in Tables 8 or 12.
  • the method of diagnosing a disease state involves detection of one or more mutations in the nucleic acid sequence of the gene.
  • Such mutations may be a substitution, a deletion, and/or an insertion of the nucleic acid sequence that results in a diseased state in the subject from which the skin sample is obtained.
  • the genes are listed in Tables 1-8, 10-12, 15, or any combination thereof. In another embodiment, the genes are listed in Tables 8 or 12.
  • kits for characterizing a skin lesion in a subject includes a skin sample collection device, such as a biopsy needle or an adhesive tape for non-invasive tape stripping, and one or more probes or primers that selectively bind to one or more nucleic acid molecules in any of Tables 1-8 and 10-12, 15, or to a nucleic acid or protein expression product of a nucleic acid molecule in any of Tables 1-8, 10-12, and 15.
  • a skin sample collection device such as a biopsy needle or an adhesive tape for non-invasive tape stripping
  • probes or primers that selectively bind to one or more nucleic acid molecules in any of Tables 1-8 and 10-12, 15, or to a nucleic acid or protein expression product of a nucleic acid molecule in any of Tables 1-8, 10-12, and 15.
  • the gene analyzed is any one or more of interferon regulatory factor 6, claudin 23, melan-A, osteopetrosis associated transmembrane protein 1, RAS-like family 11 member B, actinin alpha 4, transmembrane protein 68, Glycine-rich protein (GRP3S), Transcription factor 4, hypothetical protein FLJ20489, cytochrome c somatic, transcription factor 4, Forkhead box P1, transducer of ERBB2-2, glutaminyl-peptide cyclotransferase (glutaminyl cyclase), hypothetical protein FLJ10770, selenophosphate synthetase 2, embryonal Fyn-associated substrate, Kruppel-like factor 8, Discs large homolog 5 (Drosophila), regulator of G-protein signalling 10, ADP-ribosylation factor related protein 2, TIMP metallopeptidase inhibitor 2,5-aminoimidazole-4-carboxamide ribonucleotide formyltransfera
  • the kit for characterizing a skin lesion in a subject includes an applicator and one or more probes or primers that selectively bind to one or more nucleic acid molecules in any of Tables 1-8 and 10-12, 15, or to a nucleic acid or protein expression product of a nucleic acid molecule in any of Tables 1-8, 10-12, and 15.
  • the probes are detectably labeled for visual identification of expression of RNA.
  • FIGS. 1A and 1B are graphical diagrams showing data from the EDR, PTP, and PTN as a function of sample size, assuming a threshold for declaring the significance of a probe/gene expression difference between nevi and primary melanoma of p ⁇ 0.05.
  • FIGS. 2A and 2B are graphical diagrams showing data from a sample size analysis that considered the contrast results for nevi vs. primary melanoma in the context of an analysis of variance (ANOVA) comparing normal skin, nevi, and primary melanoma
  • ANOVA analysis of variance
  • FIGS. 3A and 3B are graphical diagrams showing data from an analysis focusing exclusively on the posterior true probability (PTP) for different assumed significance levels.
  • PTP posterior true probability
  • FIGS. 4A to 4D are pictorial and graphical diagrams showing the development of a gene classifier for distinguishing melanoma from atypical nevi and normal pigmented skin.
  • FIGS. 5A and 5B are graphical diagrams showing data from prediction analysis of the developed classifiers for distinguishing melanoma from atypical nevi and normal pigmented skin.
  • FIGS. 6A to 6E are graphical diagrams showing data from prediction analysis of the developed classifiers for distinguishing melanoma from atypical nevi and normal pigmented skin.
  • FIG. 7 is a hierarchial cluster analysis of the identified genes distinguishing melanoma from atypical nevi and normal pigmented skin.
  • FIG. 8 is a graphical diagram showing results from classification modeling of the identified genes.
  • FIG. 9 is a graphical diagram showing data of a developed classifier for distinguishing melanoma from atypical nevi and normal pigmented skin.
  • FIG. 10 is a pictorial diagram showing the development of a classifier to discriminate melanoma from atypical nevi using non-invasive tape strip-based genomic profiling.
  • FIG. 11 is a pictorial diagram describing the development of a 19-gene classifier that discriminates melanoma from atypical nevi.
  • FIG. 12 is a pictorial diagram showing a hierarchial cluster analysis of the identified genes from the 19-gene classifier identified in FIG. 11 .
  • FIG. 13 is a pictorial diagram showing results from 10 melanoma and 10 nevi samples against the 19-gene classifier identified in FIG. 11 .
  • FIG. 14 is a graphical diagram showing data of a developed classifier for distinguishing solar lentigines from normal pigmented skin.
  • FIG. 15 is a hierarchial cluster analysis of the identified genes from FIG. 14 distinguishing solar lentigines from normal pigmented skin.
  • FIG. 16 is a graphical diagram showing data from prediction analysis of the developed classifiers for distinguishing solar lentigines from normal pigmented skin.
  • FIG. 17 is a hierarchial cluster analysis of a gene expression profile distinguishing solar lentigines from atypical nevi and basal cell carcinoma.
  • FIG. 18 is a hierarchial cluster analysis of a gene expression profile distinguishing solar lentigines from lentigo maligna.
  • FIG. 19 is a hierarchial cluster analysis of a 28-gene classifier distinguishing solar lentigines from lentigo maligna.
  • the present invention is based, in part, on the discovery that analysis of nucleic acid molecules or of protein expression products of nucleic acid molecules from specific genes can be used to characterize skin lesions in a subject. Accordingly, the present invention provides methods and kits useful for detecting cancer, especially melanoma, by determining the expression profiles of one or more specific genes of interest. In addition, the present invention provides methods and kits useful for distinguishing solar lentigines from cancer by determining the expression profiles of one or more specific genes of interest.
  • melanoma is one of the best characterized carcinogenesis models for gradual progression of benign lesions to cancer: normal pigmented cells to nevi to atypical nevi to primary melanoma in situ to invasive primary melanoma to aggressive metastatic melanoma. This progression is known to correlate with distinctive chromosomal changes, and is thought to be mediated by stepwise progressive changes in gene expression, suggesting that expression profiling may identify genes responsible for tumorigenesis in melanoma. Indeed, candidate tumor genes have been identified with microarray analyses of melanoma cell lines.
  • the second reason is that molecular characterization of tumors may allow a better staging classification of tumors and prognosis prediction. While histological characteristics such as the thickness and ulceration of tumors have some value as predictors of prognosis, there is lack of informative markers that help determine which patients will do well and which patients will have progressive disease and metastasis. Molecular markers identified in microarray experiments of tumors are already being introduced into clinical practice in the management of breast cancer. Gene expression profiling experiments in melanoma and melanoma cell lines suggest that the classification of melanoma can be improved, but studies are lacking with sufficient power to define molecular criteria for diagnosis or identify prognostic markers; the establishments of such markers would represent a major advance in melanoma care.
  • subject refers to any individual or patient to which the subject methods are performed.
  • the subject is human, although as will be appreciated by those in the art, the subject may be an animal.
  • animals including mammals such as rodents (including mice, rats, hamsters and guinea pigs), cats, dogs, rabbits, farm animals including cows, horses, goats, sheep, pigs, etc., and primates (including monkeys, chimpanzees, orangutans and gorillas) are included within the definition of subject.
  • sample and “biological sample” refer to any sample suitable for the methods provided by the present invention.
  • a sample of cells can be any sample, including, for example, a skin sample obtained by non-invasive tape stripping or biopsy of a subject, or a sample of the subject's bodily fluid.
  • the biological sample of the present invention is a tissue sample, e.g., a biopsy specimen such as samples from needle biopsy.
  • sample refers to any preparation derived from skin of a subject.
  • a sample of cells obtained using the non-invasive method described herein can be used to isolate nucleic acid molecules or proteins for the methods of the present invention.
  • Samples for the present invention typically are taken from a skin lesion, which is suspected of being the result of a disease or a pathological or physiological state, such as psoriasis or dermatitis, or the surrounding margin or tissue.
  • a skin lesion which is suspected of being the result of a disease or a pathological or physiological state, such as psoriasis or dermatitis, or the surrounding margin or tissue.
  • surrounding margin or “surrounding tissue” refers to tissue of the subject that is adjacent to the skin lesion, but otherwise appears to be normal or free from lesion.
  • corresponding normal cells refers to cells or a sample from a subject that is from the same organ and of the same type as the cells being examined.
  • the corresponding normal cells comprise a sample of cells obtained from a healthy individual that does not have a skin lesion or skin cancer.
  • Such corresponding normal cells can, but need not be, from an individual that is age-matched and/or of the same sex as the individual providing the cells being examined.
  • the term “normal sample” or “control sample” refers to any sample taken from a subject of similar species that is considered healthy or otherwise not suffering from the particular disease, pathological or physiological state, or from the same subject in an area free from skin lesions.
  • a normal/standard level of RNA denotes the level of RNA present in a sample from the normal sample.
  • a normal level of RNA can be established by combining skin samples or cell extracts taken from normal healthy subjects and determining the level of one or more RNAs present.
  • a normal level of RNA also can be determined as an average value taken from a population of subjects that is considered to be healthy, or is at least free of a particular disease, pathological or physiological state. Accordingly, levels of RNA in subject, control, and disease samples can be compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing or characterizing disease.
  • skin refers to the outer protective covering of the body, consisting of the epidermis (including the stratum corneum) and the underlying dermis, and is understood to include sweat and sebaceous glands, as well as hair follicle structures.
  • cutaneous can be used, and should be understood to refer generally to attributes of the skin, as appropriate to the context in which they are used.
  • the epidermis of the human skin comprises several distinct layers of skin tissue.
  • the deepest layer is the stratum basalis layer, which consists of columnar cells.
  • the overlying layer is the stratum spinosum, which is composed of polyhedral cells.
  • stratum corneum constitute the outer layer of the epidermis, the stratum corneum.
  • stratum corneum At the bottom of the stratum corneum, the cells are closely compacted and adhere to each other strongly, but higher in the stratum they become loosely packed, and eventually flake away at the surface.
  • skin lesion refers to a change in the color or texture in an area of skin.
  • skin lesions suspected of being melanoma are skin lesions with characteristics of malignant melanoma, which are well known to those of skill in the art, such as dermatologists and oncologists. Such lesions are sometimes raised and can have a color that is different from the color of normal skin of an individual (e.g., brown, black, red, or blue). Lesions suspected of being melanoma sometimes include a mixture of colors, are often asymmetrical, can change in appearance over time, and may bleed. A skin lesion suspected of being melanoma may be a mole or nevus.
  • Melanoma lesions are usually, but not always, larger than 6 mm in diameter.
  • Melanoma includes superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.
  • the term “lentigo maligna” refers to a precancerous lesion on the skin, especially in areas exposed to the sun, that is flat, mottled, and brownish with an irregular outline and grows slowly over a period of years. Melanoma can occur on skin that has been overexposed to the sun. Therefore, in one embodiment the skin sample is taken from an area of skin that has been overexposed to the sun.
  • Dysplastic nevus refers to an atypical mole or a mole whose appearance is different from that of common moles.
  • Dysplastic nevi are generally larger than ordinary moles and have irregular and indistinct borders. Their color frequently is not uniform and ranges from pink to dark brown; they usually are flat, but parts may be raised above the skin surface.
  • Dysplastic naevus can be found anywhere, but are most common on the trunk of a subject.
  • cancer includes any malignant tumor including, but not limited to, carcinoma and sarcoma. Cancer arises from the uncontrolled and/or abnormal division of cells that then invade and destroy the surrounding tissues. As used herein, “proliferating” and “proliferation” refer to cells undergoing mitosis. As used herein, “metastasis” refers to the distant spread of a malignant tumor from its sight of origin. Cancer cells may metastasize through the bloodstream, through the lymphatic system, across body cavities, or any combination thereof.
  • cancer cells may metastasize through the bloodstream, through the lymphatic system, across body cavities, or any combination thereof.
  • cancerous cell includes a cell afflicted by any one of the cancerous conditions provided herein.
  • carcinoma refers to a malignant new growth made up of epithelial cells tending to infiltrate surrounding tissues, and to give rise to metastases.
  • melanoma refers to a malignant tumor of melanocytes which are found predominantly in skin but also in bowel and the eye.
  • melanocytes refer to cells located in the bottom layer, the basal lamina, of the skin's epidermis and in the middle layer of the eye.
  • melanoma metastasis refers to the spread of melanoma cells to regional lymph nodes and/or distant organs (e.g., liver, brain, breast, prostate, etc.).
  • BCC basal cell carcinoma
  • Basal cell carcinoma refers to a slow-growing neoplasm that is locally invasive but rarely metastasizes. It is derived from basal cells, the deepest layer of epithelial cells of the epidermis or hair follicles. BCC is a common skin cancer that is often associated with overexposure to sunlight.
  • solar lentigines also known as a sun-induced freckle or senile lentigo, is a dark (hyperpigmented) lesion caused by natural or artificial ultraviolet (UV) light.
  • Solar lentigines may be single or multiple. Solar lentigines are benign, but they do indicate excessive sun exposure, a risk factor for the development of skin cancer. The lesions tend to increase in number with age, making them common among the middle age and older population. They can vary in size from about 0.2 to 2.0 cm. These flat lesions usually have discrete borders, are dark in color, and have an irregular shape.
  • the term “gene” refers to a linear sequence of nucleotides along a segment of DNA that provides the coded instructions for synthesis of RNA, which, when translated into protein, leads to the expression of hereditary character.
  • the term “skin marker” or “biomarker” refers to a gene whose expression level is different between skin surface samples at the site of malignant melanoma and skin surface samples of normal skin or a lesion, which is benign, such as a benign nevus. Therefore, expression of a melanoma skin marker of the invention is related to, or indicative of, melanoma.
  • nucleic acid molecule means DNA, RNA, single-stranded, double-stranded or triple stranded and any chemical modifications thereof. Virtually any modification of the nucleic acid is contemplated.
  • a “nucleic acid molecule” can be of almost any length, from 10, 20, 30, 40, 50, 60, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 8000, 9000, 10,000, 15,000, 20,000, 30,000, 40,000, 50,000, 75,000, 100,000, 150,000, 200,000, 500,000, 1,000,000, 1,500,000, 2,000,000, 5,000,000 or even more bases in length, up to a full-length chromosomal DNA molecule.
  • the nucleic acid isolated from a sample is typically RNA.
  • Micro-RNAs are small single stranded RNA molecules an average of 22 nucleotides long that are involved in regulating mRNA expression in diverse species including humans (reviewed in Bartel 2004).
  • the first report of miRNA was that of the lin-4 gene, discovered in the worm C. elegans (Lee, Feinbaum et al. 1993). Since then hundreds of miRNAs have been discovered in flies, plants and mammals. miRNAs regulate gene expression by binding to the 3′-untranslated regions of mRNA and catalyze either i) cleavage of the mRNA; or 2) repression of translation.
  • miRNAs The regulation of gene expression by miRNAs is central to many biological processes such as cell development, differentiation, communication, and apoptosis (Reinhart, Slack et al. 2000; Baehrecke 2003; Brennecke, Hipfner et al. 2003; Chen, Li et al. 2004). Recently it has been shown that miRNA are active during embryogenesis of the mouse epithelium and play a significant role in skin morphogenesis (Yi, O'Carroll et al. 2006).
  • miRNAs will influence, if not completely specify the relative amounts of mRNA in particular cell types and thus determine a particular gene expression profile (i.e., a population of specific mRNAs) in different cell types.
  • a particular gene expression profile i.e., a population of specific mRNAs
  • the particular distribution of specific miRNAs in a cell will also be distinctive in different cell types.
  • determination of the miRNA profile of a tissue may be used as a tool for expression profiling of the actual mRNA population in that tissue.
  • miRNA levels and/or detection of miRNA mutations are useful for the purposes of disease detection, diagnosis, prognosis, or treatment-related decisions (i.e., indicate response either before or after a treatment regimen has commenced) or characterization of a particular disease in the subject.
  • protein refers to at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides.
  • a protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures.
  • amino acid or “peptide residue”, as used herein means both naturally occurring and synthetic amino acids. For example, homo-phenylalanine, citrulline and noreleucine are considered amino acids for the purposes of the invention.
  • Amino acid also includes imino acid residues such as proline and hydroxyproline.
  • the side chains may be in either the (R) or the (S) configuration.
  • a “probe” or “probe nucleic acid molecule” is a nucleic acid molecule that is at least partially single-stranded, and that is at least partially complementary, or at least partially substantially complementary, to a sequence of interest.
  • a probe can be RNA, DNA, or a combination of both RNA and DNA. It is also within the scope of the present invention to have probe nucleic acid molecules comprising nucleic acids in which the backbone sugar is other that ribose or deoxyribose. Probe nucleic acids can also be peptide nucleic acids.
  • a probe can comprise nucleolytic-activity resistant linkages or detectable labels, and can be operably linked to other moieties, for example a peptide.
  • a single-stranded nucleic acid molecule is “complementary” to another single-stranded nucleic acid molecule when it can base-pair (hybridize) with all or a portion of the other nucleic acid molecule to form a double helix (double-stranded nucleic acid molecule), based on the ability of guanine (G) to base pair with cytosine (C) and adenine (A) to base pair with thymine (T) or uridine (U).
  • G guanine
  • C cytosine
  • A adenine
  • T thymine
  • U uridine
  • the nucleotide sequence 5′-TATAC-3′ is complementary to the nucleotide sequence 5′-GTATA-3′.
  • antibody as used in this invention is meant to include intact molecules of polyclonal or monoclonal antibodies, as well as fragments thereof, such as Fab and F(ab) 2 , Fv and SCA fragments which are capable of binding an epitopic determinant.
  • the term “specifically binds” or “specifically interacts,” when used in reference to an antibody means that an interaction of the antibody and a particular epitope has a dissociation constant of at least about 1 ⁇ 10 ⁇ 6 , generally at least about 1 ⁇ 10 ⁇ 7 , usually at least about 1 ⁇ 10 ⁇ 8 , and particularly at least about 1 ⁇ 10 ⁇ 9 or 1 ⁇ 10 ⁇ 10 or less.
  • hybridization refers to the process by which a nucleic acid strand joins with a complementary strand through base pairing.
  • Hybridization reactions can be sensitive and selective so that a particular sequence of interest can be identified even in samples in which it is present at low concentrations.
  • suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art.
  • stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.
  • hybridization under high stringency conditions could occur in about 50% formamide at about 37° C. to 42° C.
  • Hybridization could occur under reduced stringency conditions in about 35% to 25% formamide at about 30° C. to 35° C.
  • hybridization could occur under high stringency conditions at 42° C. in 50% formamide, 5 ⁇ SSPE, 0.3% SDS, and 200 mg/ml sheared and denatured salmon sperm DNA.
  • Hybridization could occur under reduced stringency conditions as described above, but in 35% formamide at a reduced temperature of 35° C.
  • the temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.
  • Mutation refers to a change in the genome with respect to the standard wild-type sequence. Mutations can be deletions, insertions, or rearrangements of nucleic acid sequences at a position in the genome, or they can be single base changes at a position in the genome, referred to as “point mutations.” Mutations can be inherited, or they can occur in one or more cells during the lifespan of an individual.
  • kit or “research kit” refers to a collection of products that are used to perform a biological research reaction, procedure, or synthesis, such as, for example, a detection, assay, separation, purification, etc., which are typically shipped together, usually within a common packaging, to an end user.
  • ameliorating or “treating” means that the clinical signs and/or the symptoms associated with the cancer or melanoma are lessened as a result of the actions performed.
  • the signs or symptoms to be monitored will be characteristic of a particular cancer or melanoma and will be well known to the skilled clinician, as will the methods for monitoring the signs and conditions.
  • a “treatment regimen” refers to any systematic plan or course for treating a disease or cancer in a subject.
  • Samples from a tissue can be isolated by any number of means well known in the art.
  • Invasive methods for isolating a sample include, but are not limited to the use of needles or scalpels, for example during biopsies of various tissues.
  • Non-invasive methods for isolating a sample include, but are not limited to tape-stripping and skin scraping.
  • the present invention employs a non-invasive tape stripping technology to obtain samples of suspicious lesions.
  • DNA microarray assays are used to create a non-invasive diagnostic for melanoma and/or distinguishing melanoma from solar lentigo.
  • Tape-stripping removes superficial cells from the surface of the skin as well as adnexal cells. Small amounts of nucleic acid molecules isolated from tape-stripped cells can be amplified and used for microarray analyses and quantitative PCR. In addition, proteins obtained from the lysed cells may be quantitated for diagnosis of disease.
  • tape-stripping is a non-invasive diagnostic method, which does not interfere with subsequent histological analyses, thereby bypassing a major limitation to current expression profiling studies on melanoma.
  • tape stripping will primarily sample superficial cells from the epidermis, this method holds great promise in the diagnoses and prognosis prediction in pigmented lesions for the following reasons: First, in contrast to benign nevi, in many melanomas the pigmented cells migrate into the epidermis and/or adnexa. Consequently, this feature may help differentiate benign pigmented lesions from melanomas based on tape stripping. Second, there are changes in the dermis and epidermis adjacent to melanoma.
  • the epidermal hyperplasia overlying melanoma seems to correlate with both angiogenesis and metastatic potential; these changes are expected to be sampled with the tape stripping method.
  • some advanced melanomas do reach the surface of the skin and melanoma cancer cells would be sampled directly by the tape stripping.
  • tape stripping is useful in the care of patients with multiple pigmented lesions where it is unpractical to biopsy each and every lesion.
  • the present invention demonstrates that stratum corneum RNA, harvested by tape stripping with Epidermal Genetic Information Retrieval (EGIR) (see U.S. Pat. No. 6,949,338, incorporated herein by reference), can be used to distinguish melanoma from dysplastic nevi in suspicious pigmented lesions.
  • EGIR Epidermal Genetic Information Retrieval
  • the tape stripping methods provided herein typically involve applying an adhesive tape to the skin of a subject and removing the adhesive tape from the skin of the subject one or more times.
  • the adhesive tape is applied to the skin and removed from the skin about one to ten times.
  • about ten adhesive tapes can be sequentially applied to the skin and removed from the skin.
  • an adhesive tape can be applied to and removed from a target site 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 time, and/or 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 adhesive tape can be applied to and removed from the target site.
  • the adhesive tape is applied to the skin between about one and eight times, in another example, between one and five times, and in another illustrative example the tape is applied and removed from the skin four times.
  • the rubber based adhesive can be, for example, a synthetic rubber-based adhesive.
  • the rubber based adhesive in illustrative examples, has high peel, high shear, and high tack.
  • the rubber based adhesive can have a peak force tack that is at least 25%, 50%, or 100% greater than the peak force tack of an acrylic-based tape such as D-SQUAMETM.
  • D-SQUAMETM has been found to have a peak force of 2 Newtons, wherein peak force of the rubber based adhesive used for methods provided herein, can be 4 Newtons or greater.
  • the rubber based adhesive can have adhesion that is greater than 2 times, 5 times, or 10 times that of acrylic based tape.
  • D-SQUAMETM has been found to have adhesion of 0.0006 Newton meters
  • the rubber based tape provided herein can have an adhesion of about 0.01 Newton meters using a texture analyzer.
  • the adhesive used in the methods provided herein has higher peel, shear and tack than other rubber adhesives, especially those used for medical application and Duct tape.
  • adhesive tape can be fabricated into circular discs of diameter between 10 millimeters and 100 millimeters, for example between 15 and 25 millimeters in diameter.
  • the adhesive tape can have a surface area of between about 50 mm 2 and 1000 mm 2 , between about 100 mm 2 to 500 mm 2 or about 250 mm 2 .
  • the sample is obtained by means of an invasive procedure, such as biopsy.
  • Biopsies may be taken instead of or after tape stripping and are subjected to standard histopathologic analysis. Analysis of biopsy samples taken simultaneously with tape stripping samples may then be correlated with the data generated from one or more of analysis of selected lesion RNA samples by DNA microarray, correlation of gene expression data with histopathology, and creation of a candidate expression classifier for diagnosis of melanoma.
  • biopsy refers to the removal of cells or tissues for analysis.
  • biopsy procedures There are many different types of biopsy procedures known in the art. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle.
  • incisional biopsy in which only a sample of tissue is removed
  • excisional biopsy in which an entire lump or suspicious area is removed
  • needle biopsy in which a sample of tissue or fluid is removed with a needle.
  • core biopsy When a wide needle is used, the procedure is called a core biopsy.
  • fine-needle aspiration biopsy When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.
  • Other types of biopsy procedures include, but are not limited to, shave biopsy, punch biopsy, curettage biopsy, and in situ biopsy.
  • the skin sample is obtained by scraping the skin with an instrument to remove one or more nucle
  • the skin sample obtained using the tape stripping method includes, epidermal cells including cells comprising adnexal structures.
  • the sample includes predominantly epidermal cells, or even exclusively epidermal cells.
  • the epidermis consists predominantly of keratinocytes (>90%), which differentiate from the basal layer, moving outward through various layers having decreasing levels of cellular organization, to become the cornified cells of the stratum corneum layer. Renewal of the epidermis occurs every 20-30 days in uninvolved skin.
  • Other cell types present in the epidermis include melanocytes, Langerhans cells, and Merkel cells.
  • the tape stripping method of the present invention is particularly effective at isolating epidermal samples.
  • Nucleic acid molecules can also be isolated by lysing the cells and cellular material collected from the skin sample by any number of means well known to those skilled in the art. For example, a number of commercial products available for isolating polynucleotides, including but not limited to, RNeasyTM (Qiagen, Valencia, Calif.) and TriReagentTM (Molecular Research Center, Inc, Cincinnati, Ohio) can be used. The isolated polynucleotides can then be tested or assayed for particular nucleic acid sequences, including a polynucleotide encoding a cytokine. Methods of recovering a target nucleic acid molecule within a nucleic acid sample are well known in the art, and can include microarray analysis.
  • Nucleic acid molecules may be analyzed in any number of ways known in the art. For example, the presence of nucleic acid molecules can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments of the specific nucleic acid molecule. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the nucleic acid sequences to detect transformants containing the specific DNA or RNA.
  • analysis of the nucleic acid molecules includes genetic analysis is to determine the nucleotide sequence of a gene. Since a difference in length or sequence between DNA fragments isolated from a sample and those of known sequences are due to an insertion, deletion, or substitution of one or more nucleotides, the determination of nucleic acid sequences provides information concerning mutations which have absolute influence on the physiology of the disease state in the subject. These mutations may also include transposition or inversion and are difficult to detect by other techniques than direct sequencing. For example, it has recently been shown that the presence of the c-kit-activating mutation, L576P, is indicative of malignant melanomas (see Table 1). Accordingly, the methods of the present invention may be used to detect genetic mutations in one or more genes listed in Tables 1-8 and 10-12 for diagnosis and/or characterization of a skin lesion in a subject.
  • antibodies that specifically bind the expression products of the nucleic acid molecules of the invention may be used to characterize the skin lesion of the subject.
  • the antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule.
  • Means for producing labeled hybridization or PCR probes for detecting sequences related to the nucleic acid molecules of Tables 1-8, 10-12, and 15 include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide.
  • the nucleic acid molecules, or any fragments thereof may be cloned into a vector for the production of an mRNA probe.
  • RNA polymerase such as T7, T3, or SP6 and labeled nucleotides.
  • T7, T3, or SP6 RNA polymerase
  • Suitable reporter molecules or labels include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.
  • PCR systems usually use two amplification primers and an additional amplicon-specific, fluorogenic hybridization probe that specifically binds to a site within the amplicon.
  • the probe can include one or more fluorescence label moieties.
  • the probe can be labeled with two fluorescent dyes: 1) a 6-carboxy-fluorescein (FAM), located at the 5′-end, which serves as reporter, and 2) a 6-carboxy-tetramethyl-rhodamine (TAMRA), located at the 3′-end, which serves as a quencher.
  • FAM 6-carboxy-fluorescein
  • TAMRA 6-carboxy-tetramethyl-rhodamine
  • In situ PCR may be utilized for the direct localization and visualization of target nucleic acid molecules and may be further useful in correlating expression with histopathological finding.
  • Means for producing specific hybridization probes for nucleic acid molecules of the invention include the cloning of the nucleic acid sequences into vectors for the production of mRNA probes.
  • vectors are known in the art, commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides.
  • Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as 32 P or 35 S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.
  • Standard hybridization may be quantified by comparing the values obtained from subjects of known skin characterization (e.g., from subjects either having melanoma, having dysplastic nevi, and/or having solar lentigines). Standard values obtained from such samples may be compared with values obtained from samples from subjects having skin lesions that are suspected of being melanoma. Deviation between standard and subject values is used to establish the presence of disease.
  • a non-invasive sampling method for the characterization of skin lesion on the skin.
  • a sample set of pigmented skin lesions is created.
  • Each sample consists of nucleic acid molecules recovered by tape stripping or biopsy sample of the superficial epidermis overlying the lesion.
  • a standard biopsy of the same lesion may also be performed, along with accompanying histology and diagnosis. Nucleic acid molecules recovered by tape stripping the superficial epidermis of normal skin will serve as a negative control.
  • the invention provides a method of distinguishing melanoma from solar lentigo and/or dysplastic nevi and/or normal pigmented skin in a subject.
  • the method includes analyzing a nucleic acid molecule from one or more genes listed in any of Tables 1-8, 10-12, 15, or any combination thereof.
  • a target area of the skin of a subject that suspected of being melanoma is assayed for expression of a large number of genes.
  • Analyzing expression includes any qualitative or quantitative method for detecting expression of a gene, many of which are known in the art.
  • the method can include analyzing expression of specific markers by measuring expression of the markers using a quantitative method, or by using a qualitative method. Non-limiting methods for analyzing polynucleotides and polypeptides are discussed below.
  • the invention provides a method of distinguishing solar lentigines from dysplastic nevi and/or basal cell carcinoma and/or normal pigmented skin in a subject.
  • the method includes analyzing a nucleic acid molecule from one or more genes listed in any of Tables 1-8, 10-12, 15, or any combination thereof.
  • a target area of the skin of a subject that suspected of being melanoma is assayed for expression of a large number of genes.
  • Analyzing expression includes any qualitative or quantitative method for detecting expression of a gene, many of which are known in the art.
  • the method can include analyzing expression of specific markers by measuring expression of the markers using a quantitative method, or by using a qualitative method. Non-limiting methods for analyzing polynucleotides and polypeptides are discussed below
  • Methods of analyzing expression of a gene of the present invention can utilize a microarray, or other miniature high-throughput technology, for detecting expression of one or more gene products.
  • Quantitative measurement of expression levels using such microarrays is also known in the art, and typically involves a modified version of a traditional method for measuring expression as described herein. For example, such quantitation can be performed by measuring a phosphor image of a radioactive-labeled probe binding to a spot of a microarray, using a phosphohor imager and imaging software.
  • the invention provides a method for diagnosing various disease states in a subject by identifying new diagnostic markers, specifically the classification and diagnosis of melanoma.
  • the invention provides a method for distinguishing solar lentigines from dysplastic nevi and/or lentigo maligna and/or normal skin.
  • the invention provides a method for diagnosing various disease states in a subject by identifying new diagnostic markers, specifically the classification and diagnosis of melanoma. By identifying gene sets that are unique to a given state, these differences in the genetic expression can be utilized for diagnostic purposes.
  • the nucleic acid molecule is RNA, including messenger RNA (mRNA) that is isolated from a sample from the subject.
  • Up-regulated and down-regulated gene sets for a given disease state may be subsequently combined.
  • the combination enables those of skill in the art to identify gene sets or panels that are unique to a given disease state.
  • Such gene sets are of immense diagnostic value as they can be routinely used in assays that are simpler than microarray analysis (for example “real-time” quantitative PCR).
  • Such gene sets also provide insights into pathogenesis and targets for the design of new drugs.
  • a reference database containing a number of reference projected profiles is also created from skin samples of subjects with known states, such as normal (i.e., non-melanoma) and various skin cancer disease states and/or pigmented non-cancer states.
  • the projected profile is then compared with the reference database containing the reference projected profiles. If the projected profile of the subject matches best with the profile of a particular disease state in the database, the subject is diagnosed as having such disease state.
  • known states such as normal (i.e., non-melanoma) and various skin cancer disease states and/or pigmented non-cancer states.
  • Exemplary software programs include, but are not limited to, Cluster & TreeView (Stanford, URLs: rana.lbl.gov or microarray.org), GeneCluster (MIT/Whitehead Institute, URL: MPR/GeneCluster/GeneCluster.html), Array Explorer (SpotFire Inc, URL: spotfire.com/products/scicomp.asp#SAE) and GeneSpring (Silicon Genetics Inc, URL: sigenetics.com/Products/GeneSpring/index.html) (for computer systems and software, see also U.S. Pat. No. 6,203,987, incorporated herein by reference).
  • the methods of the present invention involve in situ analysis of the skin lesion for characterization thereof.
  • nucleic acid molecules do not need to be isolated from the subject prior to analysis.
  • detectably labeled probes are contacted with a cell or tissue of a subject for visual detection of expressed RNA to characterize the skin lesion.
  • the methods of the present invention can also be useful for monitoring the progression of diseases and the effectiveness of treatments. For example, by comparing the projected profile prior to treatment with the profile after treatment.
  • the method characterizes a cancer as melanoma metastasis based on analysis of one or more nucleic acid molecules from Tables 1-8.
  • the method characterizes a solar lentigo based on analysis of one or more nucleic acid molecules from Tables 10-12 and 15.
  • melanomas contain multiple cell populations characterized by diverse growth rates, karyotypes, cell-surface properties, antigenicity, immunogenicity, invasion, metastasis, and sensitivity to cytotoxic drugs or biologic agents.
  • the present invention may be used to characterize cancer of an organ as having metastasized from melanoma.
  • the methods of the present invention can also be useful for determining an appropriate treatment regimen for a subject having a specific cancer or melanoma.
  • the methods of the present invention can also be useful for determining an appropriate treatment regimen for a subject having solar lentigo.
  • the methods of the invention are useful for providing a means for practicing personalized medicine, wherein treatment is tailored to a subject based on the particular characteristics of the cancer or skin lesion in the subject. The method can be practiced, for example, by first determining whether the skin lesion is melanoma or solar lentigo, as described above.
  • the sample of cells examined according to the present method can be obtained from the subject to be treated, or can be cells of an established cancer cell line of the same type as that of the subject.
  • the established cell line can be one of a panel of such cell lines, wherein the panel can include different cell lines of the same type of disease and/or different cell lines of different diseases associated with expression of the genes of interest.
  • Such a panel of cell lines can be useful, for example, to practice the present method when only a small number of cells can be obtained from the subject to be treated, thus providing a surrogate sample of the subject's cells, and also can be useful to include as control samples in practicing the present methods.
  • the methods of the invention may be repeated on a regular basis to monitor the expression profiles of the genes of interest in the subject.
  • the results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.
  • another aspect of the invention is directed to methods for monitoring a therapeutic regimen for treating a subject having skin cancer. A comparison of the expression profile or mutations in the nucleic acid sequence of the nucleic acid molecule prior to and during therapy will be indicative of the efficacy of the therapy. Therefore, one skilled in the art will be able to recognize and adjust the therapeutic approach as needed.
  • the efficacy of a therapeutic regimen for treating a cancer over time can be identified by an absence of symptoms or clinical signs of the particular cancer in a subject at the time of onset of therapy.
  • the efficacy of a method of the invention can be evaluated by measuring a lessening in the severity of the signs or symptoms in the subject or by the occurrence of a surrogate end-point for the disorder.
  • such methods may help identify an individual as having a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms.
  • a more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.
  • the methods of the invention can be performed on a solid support (e.g., a microtiter plate, a silicon wafer, or a glass slide), wherein cell samples and/or genes of interest are positioned such that each is delineated from each other (e.g., in wells). Any number of samples or genes (e.g., 96, 1024, 10,000, 100,000, or more) can be examined in parallel using such a method, depending on the particular support used. Where samples are positioned in an array (i.e., a defined pattern), each sample in the array can be defined by its position (e.g., using an x-y axis), thus providing an “address” for each sample.
  • a solid support e.g., a microtiter plate, a silicon wafer, or a glass slide
  • Any number of samples or genes e.g., 96, 1024, 10,000, 100,000, or more
  • each sample in the array can be defined by its position (e.g., using an x-
  • An advantage of using an addressable array format is that the method can be automated, in whole or in part, such that cell samples, reagents, genes of interest, and the like, can be dispensed to (or removed from) specified positions at desired times, and samples (or aliquots) can be monitored, for example, for expression products and/or mutations in the nucleic acid sequence of the nucleic acid molecules from any one of the genes listed in Tables 1-8, 10-12, and 15.
  • the microarray can be used to monitor the expression level of large numbers of genes simultaneously (to produce a transcript image), and to identify genetic variants, mutations and polymorphisms.
  • Polynucleotides used in the microarray may be oligonucleotides that are specific to a gene or genes of interest in which at least a fragment of the sequence is known or that are specific to one or more unidentified cDNAs which are common to a particular cell type, developmental or disease state.
  • the gene of interest is examined using a computer algorithm which starts at the 5′ or more preferably at the 3′ end of the nucleotide sequence.
  • the algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray.
  • the “pairs” will be identical, except for one nucleotide which preferably is located in the center of the sequence.
  • the second oligonucleotide in the pair serves as a control.
  • the number of oligonucleotide pairs may range from two to one million.
  • the oligomers are synthesized at designated areas on a substrate using a light-directed chemical process.
  • the substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.
  • kits are provided that is useful for detecting cancer in a cell or tissue, e.g., using the methods provided by the present invention for characterizing a skin lesion in a subject.
  • a kit of the invention includes a skin sample collection device and one or more probes or primers that selectively bind to one or more of the nucleic acid molecules in any of Tables 1-8, 10-12, and 15.
  • the kit includes one or more applicators in addition to or instead of the skin sample collection device.
  • applicators are useful for in situ analysis of gene expression on the skin of a subject.
  • an applicator may be used to apply detectably labeled probes for visual detection of expressed RNA to characterize the skin lesion.
  • a kit of the invention includes a probe that binds to a portion of a nucleic acid molecule in any of Tables 1-8, 10-12, and 15.
  • the kit further includes a microarray that contains at least a fragment of a gene or a nucleic acid molecule or a protein product of any one of the genes listed in Tables 1-8, 10-12, and 15.
  • many reagents may be provided in a kit of the invention, only some of which should be used together in a particular reaction or procedure. For example, multiple primers may be provided, only two of which are needed for a particular application.
  • the kit of the invention provides a compartmentalized carrier including a first container containing a pair of primers.
  • the primers are typically a forward primer that selectively binds upstream of a gene on one strand, and a reverse primer that selectively binds upstream of a gene on a complementary strand.
  • the kits of the present invention can further include an instruction insert, e.g., disclosing methods for sample collection using the sample collection device and/or exemplary gene expression profiles for comparison with the expression profile of the sample taken from the subject.
  • epidermal cells overlying in situ or invasive melanoma including but not limited to the stratum corneum, stratum lucidum, and stratum granulosum, can be recovered by adhesive means and that the quality and quantity of gene expression in the form of RNA contained within this sample is differently expressed than from a nearby epidermal sample, i.e. that the sampled RNA is diagnostic because of the underlying melanoma.
  • changes in gene expression of specific genes are detectable in epidermal hyperplasia overlying cutaneous human melanoma samples obtained from surgical specimens of the epidermis (McCarty et al., 2003).
  • phase 1 the tape stripped specimens and biopsied sample collections were performed by the principal investigator or trained individuals delegated by the principal investigator to obtain the biopsy sample at various sites. All biopsies are subject to standard histopathologic analysis.
  • the RNA profiling phase includes, but is not limited to RNA purification and hybridization to DNA microarrays for gene expression profiling.
  • Adhesive tape was purchased from Adhesives Research (Glen Rock, Pa.) in bulk rolls. These rolls were custom fabricated into small circular discs, 17 millimeters in diameter, by Diagnostic Laminations Engineering (Oceanside, Calif.).
  • Human spleen total RNA was purchased from Ambion (catalogue # 7970; Austin, Tex.).
  • RNeasy RNA extraction kit was purchased from Qiagen (Valencia, Calif.).
  • Reverse transcriptase, PCR primers and probes, and TaqMan Universal Master Mix which included all buffers and enzymes necessary for the amplification and fluorescent detection of specific cDNAs, were purchased from Applied Biosystems (Foster City, Calif.).
  • MELT total nucleic acid isolation system was purchased from Ambion (Austin, Tex.).
  • RNA isolation was extracted from tapes using either pressure cycling technology (PCT; Garrett, Tao et al. 2002; Schumacher, Manak et al. 2002) or MELT total nucleic acid system. Tapes were extracted in pairs by insertion into a PULSETM tube (Pressure Biosciences, Gaithersburg, Md.) with 1.2 mls of buffer RLT (supplied in the Qiagen RNeasy kit). PULSETM tubes were inserted into the PCT-NEP2017 pressure cycler and the sample was extracted using the following parameters: room temperature; 5 pressure cycles of 35 Kpsi with pressure held for 20 seconds at the top and bottom of each cycle.
  • RNA from the 2 sites stripped on each subject was pooled to create a single sample from each subject.
  • RNA isolation using MELT total nucleic acid protocol Tapes were extracted in a 2 ml eppendorf tube with 192 ml MELT buffer plus 8 ml of MELT cocktail and vortexed for 10 minutes at room temperature. The MELT lysates were transferred to the dispensed binding bead master mix after spinning down for 3 minutes at >10,000 ⁇ g and washed with 300 ml of Wash Solution 1 and 2. RNAs were eluted in 100 ml of elution solution.
  • RNA mass recovered from tapes is determined by using quantitative RT-PCR with reference to a standard curve (C t, actin vs. log [RNA]; AppliedBiosystems 2001) created from commercially purchased human spleen total RNA. The average of 6 replicate C t, actin values was used to calculate the concentration of RNA in a sample with reference to the standard curve.
  • RNA amplification and array hybridization RNA was isolated by the Multi-Enzymatic Liquefaction of Tissue method (Ambion, Austin, Tex.) and amplified using the WT-Ovation pico amplification system (NuGen, San Carlos, Calif.). The amplified RNA was hybridized to Affymetrix U133 plus 2.0 microarray and data were processed and analyzed using R from Bioconductor.
  • Sample size is presented in Example 2. This analysis predicts that in order to find 25-40 genes with high predictive value (p ⁇ 0.001) for discriminating benign nevi from melanoma then approximately 30 melanomas and 30 non-melanoma lesions are needed.
  • Preprocessing GeneChip Data The image files from scanning the Affymetrix GeneChips with the Affymetrix series 3000 scanner will be converted using GCOS software (Affymetrix) to “CEL” format files. Normalization of CEL files will be carried out using software from the Bioconductor suite (on the world wide web at bioconductor.org). In particular, a robust multiarray analysis with adjustments for optical noise and binding affinities of oligonucleotide probes (Wu et al., 2006; and Wu et al., 2004) as implemented by the function “just.gcrma” in the “gcrma” package will be used to normalize the GeneChip Data.
  • classification rules will rely on resampling methods (k-fold cross-validation, the 632 plus bootstrap, and/or bagging (Hastie et al., 2001) applied to the naive Bayes classifier and the nearest shrunken centroid classifier (Tibshirani et al., 2002) and the support vector machine (SVM) which both performed well in classifying prostate tissues as malignant or benign, used in our previous work.
  • SVM support vector machine
  • the implementation likely to be used is to perform k-fold cross-validation. Within each of the k train/test cycles an initial screen of the training data for differentially expressed genes is performed and genes are ordered according to their posterior probability of differential expression.
  • Naive Bayes and nearest shrunken centroid classifiers based on the r genes with the highest posterior probability of differential expression are formed choosing enough values of r between 1 and 1024 to allow accurate interpolation of the classification error rate.
  • the “one se rule” (Brieman et al., 1984) is applied to the error rates for the test sets to choose the classifier that minimizes the error rate.
  • SVM an internal 632+ bootstrap is applied to each training sample to select the number of genes to be used in forming the classifier.
  • the “1 se rule” error rates from the k test sets are used to characterize the classification accuracy.
  • the identification of the biological links between genes that emerge from a gene expression microarray analysis can help put into context the biological meaningfulness of their expression patterns as well as help reduce the set of differentially expressed genes to be represented on a diagnostic panel based on their biology.
  • the end result of this analysis will be to define a candidate expression classifier that will be validated in future, larger clinical trials.
  • RNA, amplified cDNA and microarray data Following informed consent, the suspicious pigmented lesion was tape stripped using EGIR and then biopsied as per standard of care. The resulting RNA isolated from the EGIR tape was amplified and profiled on the Affymetrix U133 plus 2.0 GeneChip. Microarray data were normalized by the GCRMA algorithm. To assure high quality of microarray data are generated, QC metrics were established for RNA, amplified cDNA and microarray data. The quality of RNA was assessed by capillary electrophoresis using the Experion system (Biorad, Hercule, Calif.) and RNA with at least one visible 18S rRNA was further processed for RNA amplification.
  • the amplified cDNA was quantified by the Nanodrop system and quality of the amplified cDNA was also assessed by the Experion system. The yield of the amplified cDNAs greater than 5 mg and the average size distribution of the cDNAs greater than 750 nt were carried forward for microarray hybridization. Quality of the array data was further assessed using simpleaffy program in R and the array data with scaling factor less than 5.0 and % present call greater than 30% were used for further data analysis.
  • the PAM software uses a modification of the nearest centroid method, which computes a standardized centroid for each class in a training set. This refers to the average gene expression for each gene in each class divided by the within-class standard deviation for that gene.
  • Nearest centroid classification takes the gene expression profile of a new sample, and compares it to each of these class centroids. The class, whose centroid it is closest to, in squared distance, is the predicted class for that new sample.
  • dysplastic nevi genes were all subjected to a hierarchical clustering analysis and the melanoma specimens grouped together and were clearly distinguished from dysplastic nevi and normal skin.
  • dysplastic nevi there are three distinct classes of dysplastic nevi; one is grouped together with normal skin and the second one was in between normal skin and melanomas, while the third one was grouped together with melanomas.
  • stratum corneum RNA harvested by tape stripping with EGIR, can be used to distinguish melanoma from dysplastic nevi in suspiciously pigmented lesions.
  • Random Forests analysis is based on Bagging Predictors, which is a method for generating multiple versions of a predictor and using these to get an aggregated predictor.
  • the aggregation averages over the versions when predicting a numerical outcome and does a plurality vote when predicting a class.
  • the multiple versions are formed by making bootstrap replicates of the learning set and using these as new learning sets. Tests on real and simulated data sets using classification and regression trees and subset selection in linear regression show that bagging can give substantial gains in accuracy. If perturbing the learning set can cause significant changes in the predictor constructed, then bagging can improve accuracy.
  • TREENET® Class Modeling—TREENET®. 82 additional genes were identified (Table 7). TREENET® software (Salford Systems, San Diego, Calif.) was used to identify a 20-gene panel (Table 8), which may all be used to discriminate melanomas from atypical nevi (see FIG. 9 ). An additional 19-gene classifier was identified from 7199 differentially expressed genes between melanoma and nevi (Table 6; see also FIGS. 11 and 12 ). The 19-gene classifier was tested against independent samples and shown to be 100% sensitive and 88% specific for detection of melanomas. In addition, results from 10 melanomas and 10 nevi indicated that qRT-PCR recapitulated the data obtained using the GeneChip microarray ( FIG. 12 and see raw data in Tables 13 and 14).
  • TREENET® is a data mining tool that is based on boosted decision trees.
  • TREENET® is a model building and function approximation system that also serves as an initial data exploration tool. It can extract relationships in data and calibrate how predictable the outcomes will be, and can handle both classification and regression problems.
  • EDR Expected Discovery Rate (from Table 9, D/(B+D)). This reflects the expected proportion of probes/genes that will be declared significantly differentially expressed at the defined threshold (here taken to be, for the most part, p ⁇ 0.05) that are, in fact, differentially expressed between nevi and primary melanomas.
  • PTP Expected Proportion of probes/genes that are True Positives (Table 9, D/(C+D)). This proportion reflects the number of probes/genes showing expression differences that are likely to be truly differential expressed out of the total number of genes whose expression values result in test statistics less than the threshold (e.g., 0.05).
  • PTN Probability of a True Negative result (Table 9, A/(A+B)). This probability concerns probes/genes that are not significantly different at the assumed threshold (e.g., 0.05) that are, in fact, not differentially expressed between skin and melanoma.
  • FIG. 1 a provides a plot of the EDR, PTP, and PTN as a function of sample size, assuming a threshold for declaring the significance of a probe/gene expression difference between nevi and primary melanoma of p ⁇ 0.05.
  • a more stringent threshold for statistical significance e.g., 0.001
  • FIGS. 2 a and 2 b display the results of these analyses and provide similar sample size guidelines to those reflected in FIGS. 1 a and 1 b.
  • FIGS. 3 a and 3 b reflect the results for different assumed significance levels.
  • the following procedure was used to recover nucleic acids from normal skin (e.g., the mastoid or upper back areas) of a subject.
  • Tapes were handled with gloved hands at all times. Locate a particular site that is relatively blemish-free and healthy, unless otherwise specified by the protocol. Preferred normal skin sites are the mastoid process (the bony process behind the ear at the base of the skull) and the upper back, immediately superior to the scapular spine. Shave the site if necessary to remove non-vellus hairs. Cleanse the site with an alcohol wipe (70% isopropyl alcohol). Let the site air dry completely before application of the tape. It is recommended to wait approximately 2 minutes to ensure the site is completely dry before application of the tape.
  • the site may stripped with a total of at least four tapes, unless otherwise specified in the protocol. Place the strip into a storage bag and immediately place the samples on dry ice or into storage at ⁇ 20° C. or below until analysis.
  • lesional skin should have a preoperative biopsy diameter of greater than or equal to about 6 mm, but less than that of the tape disc. Multiple lesions must be at least about 4 mm apart.
  • the area of tape that touches the lesion should be generously demarcated on the tape with an insoluble ink pen so that this area may be cut away from the surrounding tape at the laboratory as part of the RNA extraction procedure.
  • stratum corneum RNA harvested by tape stripping with EGIR can be used to distinguish melanoma from atypical nevi in suspicious pigmented lesions. See FIG. 4A .
  • Total RNA 200-500 pg was then amplified using the WT-Ovation Pico RNA Amplification System (NuGen, Inc.) and assayed for gene expression profile using the U133 plus 2.0 GeneChip (Affymetrix, Inc.).
  • RNA isolated from the EGIR tape is then amplified and profiled on the Affymetrix U133 plus 2.0 GeneChip.
  • Microarray data is normalized by the GCRMA algorithm. Further analyses by means of ANOVA analysis (p ⁇ 0.05) with a false discovery rate of 0.05 and multiple correction testing using Westfall and Young permutation identified approximately 117 genes as differentially expressed between melanoma, dysplastic nevi and normal skin (Table 1). Hierarchical clustering of these genes showed that the melanoma specimens grouped together and were clearly distinguished from dysplastic nevi and normal skin ( FIG. 4B ).
  • RNA harvested by EGIR technology is more than adequate for microarray-based gene expression profiling and appropriately reflects the pathologic state of skin.
  • stratum corneum RNA can be used to distinguish solar lentigines from melanoma, atypical nevi, and/or normal skin in suspicious pigmented lesions.
  • TTC3 tetratricopeptide repeat domain 3 210645_s_at TTC3: tetratricopeptide repeat domain 3 206630_at TYR: tyrosinase (oculocutaneous albinism IA) 203544_s_at STAM: signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 230741_at —: Full length insert cDNA clone YX74D05
  • tyrosinase-related protein 1 206427_s_at MLANA: melan-A 206140_at LHX2: LIM homeobox 2 206630_at TYR: tyrosinase (oculocutaneous albinism IA) 203921_at CHST2: carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 205337_at
  • DCT dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) 228245_s_at OVOS2: ovostatin 2 /// similar to cDNA sequence BC048546 205338_s_at DCT: dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-related protein 2) 1557797_a_at ZFHX1B: Zinc finger homeobox

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Library & Information Science (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
US12/991,685 2008-05-14 2009-05-14 Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis Abandoned US20110160080A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/991,685 US20110160080A1 (en) 2008-05-14 2009-05-14 Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12773108P 2008-05-14 2008-05-14
US5398808P 2008-05-16 2008-05-16
US5814908P 2008-06-02 2008-06-02
US12/991,685 US20110160080A1 (en) 2008-05-14 2009-05-14 Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis
PCT/US2009/044035 WO2009140550A2 (fr) 2008-05-14 2009-05-14 Diagnostic de mélanome et de lentigo solaire par analyse d'acides nucléiques

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044035 A-371-Of-International WO2009140550A2 (fr) 2008-05-14 2009-05-14 Diagnostic de mélanome et de lentigo solaire par analyse d'acides nucléiques

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/172,784 Continuation US20140154684A1 (en) 2008-05-14 2014-02-04 Diagnosis of melanoma and solar lentigo by nucleic acid analysis

Publications (1)

Publication Number Publication Date
US20110160080A1 true US20110160080A1 (en) 2011-06-30

Family

ID=41319348

Family Applications (8)

Application Number Title Priority Date Filing Date
US12/991,685 Abandoned US20110160080A1 (en) 2008-05-14 2009-05-14 Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis
US14/172,784 Abandoned US20140154684A1 (en) 2008-05-14 2014-02-04 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US14/199,900 Active US9057109B2 (en) 2008-05-14 2014-03-06 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US14/832,966 Active 2030-06-06 US10407729B2 (en) 2008-05-14 2015-08-21 Diagnosis of melanoma by nucleic acid analysis
US16/522,291 Active 2029-08-12 US11332795B2 (en) 2008-05-14 2019-07-25 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US17/195,541 Active 2029-10-02 US11753687B2 (en) 2008-05-14 2021-03-08 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US17/217,568 Pending US20210246514A1 (en) 2008-05-14 2021-03-30 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US17/217,573 Pending US20210222258A1 (en) 2008-05-14 2021-03-30 Diagnosis of melanoma and solar lentigo by nucleic acid analysis

Family Applications After (7)

Application Number Title Priority Date Filing Date
US14/172,784 Abandoned US20140154684A1 (en) 2008-05-14 2014-02-04 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US14/199,900 Active US9057109B2 (en) 2008-05-14 2014-03-06 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US14/832,966 Active 2030-06-06 US10407729B2 (en) 2008-05-14 2015-08-21 Diagnosis of melanoma by nucleic acid analysis
US16/522,291 Active 2029-08-12 US11332795B2 (en) 2008-05-14 2019-07-25 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US17/195,541 Active 2029-10-02 US11753687B2 (en) 2008-05-14 2021-03-08 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US17/217,568 Pending US20210246514A1 (en) 2008-05-14 2021-03-30 Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US17/217,573 Pending US20210222258A1 (en) 2008-05-14 2021-03-30 Diagnosis of melanoma and solar lentigo by nucleic acid analysis

Country Status (8)

Country Link
US (8) US20110160080A1 (fr)
EP (2) EP2294216A4 (fr)
JP (1) JP2011520451A (fr)
CN (1) CN102089444A (fr)
AU (1) AU2009246180B2 (fr)
BR (1) BRPI0913578A2 (fr)
CA (1) CA2724322C (fr)
WO (1) WO2009140550A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274908A1 (en) * 2007-05-04 2008-11-06 Dermtech International Diagnosis of melanoma by nucleic acid analysis
WO2013148806A1 (fr) * 2012-03-30 2013-10-03 The Procter & Gamble Company Procédé d'élaboration d'une architecture de données permettant d'identifier des agents agissant sur la pigmentation cutanée
WO2014210467A1 (fr) * 2013-06-28 2014-12-31 Dermtech International Diagnostic de mélanome par analyse d'acide nucléique
US9057109B2 (en) 2008-05-14 2015-06-16 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
US10072293B2 (en) 2011-03-31 2018-09-11 The Procter And Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
USD966300S1 (en) 2021-02-16 2022-10-11 Dermtech, Inc. Computer display panel with a graphical user interface for a dermatology report
USD966299S1 (en) 2021-02-16 2022-10-11 Dermtech, Inc. Computer display panel with a graphical user interface for a dermatology report
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
USD988399S1 (en) 2021-02-16 2023-06-06 Dermtech, Inc. Dermatology report document
USD989861S1 (en) 2021-02-16 2023-06-20 Dermtech, Inc. Dermatology report document
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685382C (fr) 2007-05-01 2023-02-21 The Regents Of The University Of California Procedes de diagnostic d'ischemie
CA2804763C (fr) 2010-07-14 2023-01-03 The Regents Of The University Of California Biomarqueurs utilises pour le diagnostic d'accidents ischemiques transitoires
US20120065087A1 (en) 2010-07-15 2012-03-15 Regents Of The University Of California Biomarkers for diagnosis of stroke and its causes
WO2012121978A2 (fr) 2011-03-04 2012-09-13 The Regents Of The University Of California Biomarqueurs pour diagnostic d'accident vasculaire cérébral lacunaire
US20150307940A1 (en) * 2011-04-22 2015-10-29 L'oreal Molecular signature of cutaneous pigmentary spots, associated with the extracellular matrix
FR2974370B1 (fr) * 2011-04-22 2016-09-02 Oreal Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad
FR2974372B1 (fr) * 2011-04-22 2016-09-02 Oreal Signature moleculaire des taches pigmentaires cutanees, associee au remodelage de la matrice extracellulaire
FR2974373B1 (fr) * 2011-04-22 2016-09-02 Oreal Signature moleculaire des taches pigmentaires cutanees, associee a la matrice extracellulaire
FR2974371B1 (fr) * 2011-04-22 2016-10-28 Oreal Signature moleculaire des taches pigmentaires cutanees, associee a la famille des proteoglycanes et glycoproteines extracellulaires
ES2721178T3 (es) * 2011-04-22 2019-07-29 Oreal Firma molecular de manchas cutáneas pigmentarias, asociada con la organización de la matriz extracelular
WO2013103781A1 (fr) 2012-01-07 2013-07-11 The Regents Of The University Of California Biomarqueurs permettant de diagnostiquer l'ischémie.
CA2875710C (fr) * 2012-06-22 2021-06-29 John Wayne Cancer Institute Malignite moleculaire dans des lesions melanocytiques
KR102017562B1 (ko) * 2013-03-13 2019-09-03 (주)아모레퍼시픽 미백 효능 물질의 스크리닝 방법
EP3798316A3 (fr) 2013-03-15 2021-06-09 Myriad Genetics, Inc. Gènes et signatures génétiques pour le diagnostic et le traitement du mélanome
FR3015525B1 (fr) * 2013-12-20 2017-06-09 Oreal Biomarqueur rnase 7 du lentigo actinique
FR3015524B1 (fr) * 2013-12-20 2016-06-03 Oreal Signature moleculaire du lentigo actinique specifique des peaux asiatiques
FR3015526B1 (fr) * 2013-12-20 2017-02-17 Oreal Biomarqueur npy1r du lentigo actinique
FR3015523B1 (fr) * 2013-12-20 2020-05-29 L'oreal Signature moleculaire du lentigo actinique
EP3164508B1 (fr) 2014-07-02 2023-06-07 Myriad myPath, LLC Gènes et signatures génétiques pour le diagnostic et le traitement du mélanome
JPWO2016152352A1 (ja) * 2015-03-20 2018-01-11 国立大学法人名古屋大学 メラノーマ特異的バイオマーカー及びその利用
US20190086392A1 (en) * 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
EP3719138B1 (fr) 2016-07-08 2022-09-21 Kao Corporation Procédé de préparation d'échantillon d'acide nucléique
WO2019217478A1 (fr) 2018-05-09 2019-11-14 Dermtech, Inc. Nouveaux classificateurs de gènes et leurs utilisations dans des maladies auto-immunes
EP3947740A4 (fr) * 2019-04-05 2022-12-21 Dermtech, Inc. Nouveaux classificateurs de gènes destinés à être utilisés dans la surveillance d'une lésion uv
EP3883149A1 (fr) * 2020-03-20 2021-09-22 Volkswagen Ag Procédé, appareil et programme informatique permettant de prédire une qualité de service future d'un lien de communication sans fil
WO2022035075A1 (fr) * 2020-08-10 2022-02-17 주식회사 큐티스의 생명연구센터 Kit minimalement invasif pour diagnostiquer l'état de la peau, comprenant un timbre à micro-aiguilles
CA3199922A1 (fr) * 2020-11-24 2022-06-02 John Daniel Dobak Iii Evaluation de la charge mutationnelle dans la peau
WO2022221326A1 (fr) * 2021-04-13 2022-10-20 Dermtech, Inc. Classificateurs de gènes et leurs utilisations
WO2023015286A1 (fr) * 2021-08-05 2023-02-09 The Regents Of The University Of California Chirurgie du mélanome guidée par l'expression gène/protéine
FR3135992A1 (fr) * 2022-05-25 2023-12-01 L'oreal Signature moléculaire du lentigo actinique associée à la gestion des vésicules

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050221334A1 (en) * 2004-03-31 2005-10-06 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
WO2006002433A2 (fr) * 2004-06-24 2006-01-05 Veridex, Llc Procedes et reactifs pour la detection de melanome
US20060040335A1 (en) * 2004-06-21 2006-02-23 Butt Tauseef R Diagnostic and screening methods and kits associated with proteolytic activity
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
US20070281314A1 (en) * 2006-04-20 2007-12-06 Dermtech International Methods for capture and detection of micro-RNA molecules from the skin by non-invasive tape stripping

Family Cites Families (248)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441430A (en) 1964-11-19 1969-04-29 Minnesota Mining & Mfg Adhesives and adhesive tapes
US4122947A (en) 1978-01-27 1978-10-31 Falla Marjorie B Pre-packaged patient identification kit
JPS567007A (en) 1979-06-29 1981-01-24 Toshiba Corp Coating film thickness measuring apparatus
GB2061598B (en) 1979-10-15 1983-03-02 Chloride Silent Power Ltd Filling sodium-sulphur cells
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
JPS57156456A (en) 1981-03-24 1982-09-27 Shizuoka Daigaku Preparation of 1,5,5-trimethyl-3-amino-4-cyanocyclohexa-1,3- diene and its derivative
US4388432A (en) 1981-12-15 1983-06-14 Permacel Repulpable acrylic acid based pressure-sensitive adhesive
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
SE443914B (sv) 1984-10-01 1986-03-17 Torkel Ingemar Fischer Medel for en overkenslighetstest
US4851510A (en) 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4777964A (en) 1986-01-02 1988-10-18 David Briggs System for obtaining blood samples and submitting for testing of aids
US5460939A (en) 1986-04-18 1995-10-24 Advanced Tissue Sciences, Inc. Temporary living skin replacement
US4971800A (en) 1988-07-08 1990-11-20 The Regents Of The University Of California Method and compositions for enhancing the cutaneous penetration of pharmacologically active agents
US5493009A (en) 1989-11-14 1996-02-20 New York Medical College Antiidiotypic monoclonal antibodies MK2-23 anti-melanomal antibody 763.74
DK0461496T3 (da) 1990-06-08 1997-01-06 Behringwerke Ag Fremgangsmåde til kvantitativ bestemmelse af DNA-sekvenser
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5583032A (en) 1992-10-21 1996-12-10 The Cleveland Clinic Foundation And National Institutes Of Health Method of cleaving specific strands of RNA
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US5654286A (en) 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
DE69424423T2 (de) 1993-07-08 2001-01-25 Avery Dennison Corp Druckempfindliche mischklebstoffe auf der basis von acrylat gesättigten kautschuken
WO1995006137A1 (fr) 1993-08-27 1995-03-02 Australian Red Cross Society Detection de genes
US5843657A (en) 1994-03-01 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Isolation of cellular material under microscopic visualization
US5989815A (en) 1994-03-18 1999-11-23 University Of Utah Research Foundation Methods for detecting predisposition to cancer at the MTS gene
US5962477A (en) 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US7625697B2 (en) 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
JPH0852142A (ja) 1994-07-01 1996-02-27 Medical Biopsy Inc 試料保持手段を備えた生検針組立体及びその使用方法
IT1278052B1 (it) 1995-03-14 1997-11-17 Mendes Srl Uso delle immunoglobuline della classe g, in particolare delle immunoglobuline per uso endovenoso o per uso intramuscolare, per
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
US6852487B1 (en) 1996-02-09 2005-02-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6312909B1 (en) 1996-03-29 2001-11-06 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis prevention and treatment of tumor progression
US6054277A (en) 1996-05-08 2000-04-25 Regents Of The University Of Minnesota Integrated microchip genetic testing system
US5811239A (en) 1996-05-13 1998-09-22 Frayne Consultants Method for single base-pair DNA sequence variation detection
EP1736554B1 (fr) 1996-05-29 2013-10-09 Cornell Research Foundation, Inc. Detection de differences dans des sequences d'acides nucleiques utilisant une combinaison de la detection par ligase et de reactions d'amplification en chaine par polymerase
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5858683A (en) 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US5921396A (en) 1997-01-21 1999-07-13 Brown, Jr.; Jacob T. Specimen collection kit for mailing and method of using same
US6056859A (en) 1997-02-12 2000-05-02 Lockheed Martin Energy Research Corporation Method and apparatus for staining immobilized nucleic acids
DE19733014A1 (de) 1997-07-31 1999-02-04 Beiersdorf Ag Selbstklebeband
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20020006913A1 (en) 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
US6054276A (en) 1998-02-23 2000-04-25 Macevicz; Stephen C. DNA restriction site mapping
US6106732A (en) 1998-04-16 2000-08-22 Binax Services, Inc. Integral blood plasma or serum isolation, metering and transport device
US6891022B1 (en) 1998-04-23 2005-05-10 Genentech, Inc. NSP molecules
JP3813818B2 (ja) 1998-05-01 2006-08-23 アリゾナ ボード オブ リージェンツ オリゴヌクレオチドおよびｄｎａ分子のヌクレオチド配列の決定方法
US6780591B2 (en) 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
ES2358175T3 (es) 1998-08-18 2011-05-06 Dermtech International Procedimiento para la detección de factores biológicos en la epidermis.
KR100326937B1 (ko) 1998-09-23 2002-03-13 정연보 접착성 쉬트로 사람의 표피 ｄｎａ 샘플을 획득하는 방법
US6176836B1 (en) 1998-09-25 2001-01-23 David Trudil Biological sample collection kit
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
US7700324B1 (en) 1998-11-03 2010-04-20 The Johns Hopkins University School Of Medicine Methylated CpG island amplification (MCA)
CA2702148C (fr) 1999-01-06 2014-03-04 Genenews Inc. Methode de profilage de l'expression genique d'un sujet humain atteint d'une maladie infectieuse
US7094533B1 (en) 1999-01-21 2006-08-22 Board Of Regents Of The University Of Nebraska Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
US6274362B1 (en) 1999-02-04 2001-08-14 Millennium Pharmaceuticals, Inc. RGS-containing molecules and uses thereof
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
DE60037817D1 (de) 1999-08-12 2008-03-06 Wisconsin Alumni Res Found Identifizierung genetischer marker des biologischen alters und des metabolismus
AUPQ265899A0 (en) 1999-09-03 1999-09-30 Genetic Solutions Pty Ltd Sampling system
AU7987800A (en) 1999-09-29 2001-04-30 Lifespan Biosciences, Inc. Anti-aging nucleic acid and protein targets
US6447463B1 (en) 1999-11-10 2002-09-10 Piotr Borkowski Highly sensitive, practical, widely available diagnostic kit for fungal skin infections
US6726971B1 (en) 1999-12-13 2004-04-27 Tyco Adhesives Lp Thermally stable clear polyurethane adhesive tape
IL133976A (en) 2000-01-11 2006-09-05 Dermipsor Ltd Agents for the treatment of skin disorders
US7611869B2 (en) 2000-02-07 2009-11-03 Illumina, Inc. Multiplexed methylation detection methods
JP2001228449A (ja) * 2000-02-14 2001-08-24 Hamamatsu Photonics Kk レーザ集光装置及びレーザ加工装置
CA2408253A1 (fr) 2000-05-09 2001-11-15 Genetics Institute, Llc Compositions, kits, et procedes pour l'identification, l'evaluation, la prevention, et la therapie du psoriasis
EP1176200A3 (fr) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives
US7105292B2 (en) 2000-09-08 2006-09-12 New York University Screening methods used to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
US20020165192A1 (en) 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
US20030017573A1 (en) * 2000-10-04 2003-01-23 Board Of Regents, The University Of Texas System Polymerase kappa compositions and methods thereof
DE10100121A1 (de) 2001-01-03 2002-08-01 Henkel Kgaa Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US6642298B2 (en) 2001-03-16 2003-11-04 National Starch And Chemical Investment Holding Corporation Rubber-acrylic adhesive formulation
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
DE10130800B4 (de) 2001-06-22 2005-06-23 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität
WO2003001985A2 (fr) 2001-06-28 2003-01-09 Dermtech International Methode de depistage de melanome
US6749792B2 (en) 2001-07-09 2004-06-15 Lifescan, Inc. Micro-needles and methods of manufacture and use thereof
JP2003029201A (ja) 2001-07-11 2003-01-29 Canon Inc 画像投射装置及び画像補正方法
US20030133936A1 (en) 2001-07-12 2003-07-17 Byrne Michael Chapman CD25markers and uses thereof
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US6857262B2 (en) 2001-08-16 2005-02-22 Spx Corporation Catalytic converter function detection
JPWO2003032259A1 (ja) * 2001-09-27 2005-01-27 富士通株式会社 ネットワークを介したコンテンツ・データの効率的なダウンロード
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
US6692032B2 (en) * 2001-11-28 2004-02-17 Melanie Ann Christy Mole monitoring system
US20030113906A1 (en) 2001-12-14 2003-06-19 Sangha Jangbir S. Method and apparatus for DNA collection
US7921999B1 (en) 2001-12-20 2011-04-12 Watson Laboratories, Inc. Peelable pouch for transdermal patch and method for packaging
US20090082265A1 (en) 2002-01-04 2009-03-26 Myriad Genetics, Incorporated Compositions and methods for treating diseases
US7396871B2 (en) 2002-01-14 2008-07-08 Eastman Chemical Comapny Rubber modified acrylic and/or vinyl hybrid resins
AU2003212878A1 (en) 2002-01-30 2003-09-02 Epigenomics Ag Identification of cell differentiation states based on methylation patterns
US20030167556A1 (en) 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US20030224422A1 (en) 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
WO2004046098A2 (fr) 2002-05-16 2004-06-03 Vanderbilt University Technique de prevision de maladies auto-immunes
US7217853B2 (en) 2002-05-24 2007-05-15 Corium International, Inc. Composition for cushions, wound dressings and other skin-contacting products
US7267951B2 (en) 2002-06-05 2007-09-11 Sloan-Kettering Institute For Cancer Research Method for evaluating a tissue or biopsy sample to determine if the sample is early-stage melanoma
EP1534865A4 (fr) 2002-06-26 2005-12-21 Cold Spring Harbor Lab Procedes et compositions pour determiner des profils de methylation
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
WO2004024077A2 (fr) 2002-09-11 2004-03-25 Genentech, Inc. Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
US20070077553A1 (en) 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
CA2504144A1 (fr) 2002-11-26 2004-06-10 Genentech, Inc. Compositions et procedes pour le diagnostic de maladies de nature immune au moyen d'un polypeptide pro7
US20040191782A1 (en) 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
US7640114B2 (en) 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
KR20060031809A (ko) 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005012578A1 (fr) 2003-07-31 2005-02-10 Sequenom, Inc. Methodes d'amplifications en chaine par polymerase mutliplexees a haut niveau et de reactions d'extension de masse homogene pour le genotypage de polymorphismes
EP1510577A1 (fr) 2003-08-29 2005-03-02 Qiagen GmbH Méthode pour l'isolation des acides nucléiques en utilisant des particules magnétiques
IL157786A (en) 2003-09-07 2010-11-30 Ahava Dead Sea Lab Ltd Personalized cosmetics
US9217694B2 (en) 2003-10-21 2015-12-22 Leica Microsystems Cms Gmbh Method for automatically generating laser cutting lines in laser microdissection processes
ES2382780T3 (es) 2003-10-21 2012-06-13 Orion Genomics, Llc Procedimientos para la determinación cuantitativa de la densidad de metilación en un locus de ADN
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
EP1557449A1 (fr) 2004-01-22 2005-07-27 3M Innovative Properties Company Ruban adhésif pour assemblage structurel
US20050261210A1 (en) 2004-02-19 2005-11-24 Bhatnagar Rajiv S Nonsense suppressor agents in treatment of cutaneous and gastrointestinal disorders
US20050202479A1 (en) 2004-02-27 2005-09-15 Nuvelo, Inc. Methods and materials relating to insulin growth factor-like (IGFL) polypeptides and polynucleotides
WO2005085477A1 (fr) 2004-03-02 2005-09-15 Orion Genomics Llc Fragmentation enzymatique differentielle par l'amplification de genome entier
JP4526839B2 (ja) 2004-03-05 2010-08-18 株式会社資生堂 角層中の酸化タンパク質を指標とする角層の透明性・保水性を評価する方法
US7501247B2 (en) 2004-05-03 2009-03-10 Schering Corporation Method of treating skin inflammation
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
JP4790231B2 (ja) 2004-06-17 2011-10-12 花王株式会社 表皮の解析方法
US7635563B2 (en) 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
WO2006010150A2 (fr) 2004-07-15 2006-01-26 University Of Utah Research Foundation Gènes domestiques et méthodes d'identification desdits gènes
WO2006039399A2 (fr) * 2004-09-29 2006-04-13 University Of Rochester Decroissance de l'arnm mediee par staufen 1 (stau1)
DE602005016831D1 (fr) 2004-10-19 2009-11-05 Univ Kumamoto
US7643818B2 (en) 2004-11-22 2010-01-05 Seven Networks, Inc. E-mail messaging to/from a mobile terminal
ATE443161T1 (de) 2004-11-29 2009-10-15 Univ Regensburg Klinikum Mittel und verfahren für den nachweis von methylierter dna
EP1860437B1 (fr) 2005-03-18 2016-09-21 Shiseido Company, Limited Procédé permettant d'évaluer l'état de la peau en utilisant comme mesure un antigène associé au carcinome de cellules squameuses
AU2006235271B2 (en) * 2005-04-07 2011-05-19 Novartis Vaccines And Diagnostics Inc. SEMA4D in cancer diagnosis, detection and treatment
EP1869222A4 (fr) 2005-04-15 2010-01-20 Oncomethylome Sciences S A Marqueur de méthylation pour le diagnostic et le traitement des cancers
JP2008545418A (ja) 2005-05-27 2008-12-18 ジョン ウェイン キャンサー インスティチュート 癌の診断、予後診断、および治療のための遊離循環ｄｎａの使用
US20070082347A1 (en) 2005-06-08 2007-04-12 Myriad Genetics, Incorporated Gene variants and use thereof
WO2006135886A2 (fr) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions et methodes pour le traitement et le diagnostic du cancer
JP2007050126A (ja) 2005-08-18 2007-03-01 Dr Ito Procare Cosmetics:Kk 美容方法
KR101318521B1 (ko) 2005-08-23 2013-10-16 가오루 미야자키 피부 노화 마커와 그의 이용기술
US7608395B2 (en) 2005-09-15 2009-10-27 Baylor Research Institute Systemic lupus erythematosus diagnostic assay
US20070243537A1 (en) 2006-04-14 2007-10-18 Tuck Edward F Human sample matching system
CN103149368B (zh) 2005-10-21 2015-06-10 株式会社芳珂 特应性皮炎标记物及其利用技术
US20090299640A1 (en) 2005-11-23 2009-12-03 University Of Utah Research Foundation Methods and Compositions Involving Intrinsic Genes
EP1971868A2 (fr) 2006-01-05 2008-09-24 Galderma Research & Development, S.N.C. Biomarqueurs de lesions acneiques et leurs modulateurs
JP5027528B2 (ja) 2006-03-02 2012-09-19 株式会社ファンケル 皮膚老化の検査方法
CN101473045B (zh) 2006-04-24 2016-08-03 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物
EP2029171A1 (fr) 2006-06-19 2009-03-04 Wyeth a Corporation of the State of Delaware Procédés de modulation de l'il-22 et de l'il-17
US20090317840A1 (en) 2006-07-27 2009-12-24 Heinrichs Jon H Automated determination of chlamydia infection-forming units
ES2484142T3 (es) 2006-09-06 2014-08-11 The Regents Of The University Of California Diagnóstico molecular y clasificación del melanoma maligno
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
US20080070883A1 (en) 2006-09-19 2008-03-20 Wyeth Use of LXR modulators for the prevention and treatment of skin aging
EP2069377A4 (fr) 2006-09-27 2009-11-11 Univ California Procédés et compositions pour le traitement de maladies et de troubles de la peau
EP2102367A2 (fr) 2006-11-09 2009-09-23 XDX, Inc. Procedes pour diagnostiquer et surveiller l'etat d'un lupus erythemateux systemique
GB0700374D0 (en) 2007-01-09 2007-02-14 Oncomethylome Sciences S A NDRG family methylation markers
EP2125659B1 (fr) 2007-02-01 2016-01-13 Siemens Healthcare Diagnostics Inc. Particules magnetiques de silice ayant une capacite de liaison elevee aux acides nucleiques
NZ580710A (en) * 2007-05-04 2012-06-29 Dermtech Int Diagnosis of melanoma by nucleic acid analysis
US8911937B2 (en) 2007-07-19 2014-12-16 Brainreader Aps Method for detecting methylation status by using methylation-independent primers
US8389215B2 (en) 2007-07-26 2013-03-05 University Of Utah Research Foundation Non-invasive recovery of RNA and analysis of gene expression in skin
EP2184997A4 (fr) 2007-07-31 2010-11-03 Univ New York Procédés de diagnostic et de traitement pour caractériser des microbiotes bactériens dans des affections de la peau
WO2009021141A1 (fr) 2007-08-07 2009-02-12 The Johns Hopkins University Réseaux complets à rendement élevé pour méthylation relative
US20090047309A1 (en) 2007-08-13 2009-02-19 Maes Daniel H Cosmetic methods and compositions for repairing human skin
US7965820B2 (en) 2007-08-17 2011-06-21 Brookhaven Science Associates, Llc Fiducial marker for correlating images
KR100999261B1 (ko) 2007-10-09 2010-12-07 (주)아모레퍼시픽 여성호르몬 결핍으로 초래되는 여성 피부의 노화 억제제 스크리닝 방법
EP2053131A1 (fr) 2007-10-19 2009-04-29 Ludwig-Maximilians-Universität München Procédé pour déterminer la méthylation de résidus de déoxycytosine
WO2009053493A1 (fr) 2007-10-26 2009-04-30 Galderma Research & Development Procédé non invasif pour études pharmaco-génomiques de maladies inflammatoires cutanées et leur procédé de diagnostic
US20090246768A1 (en) 2008-02-15 2009-10-01 Sawalha Amr H Predicting and Diagnosing Patients With Autoimmune Disease
NZ587750A (en) 2008-03-05 2012-10-26 Univ California Molecular diagnosis and classification of malignant melanoma
JP2011516061A (ja) 2008-04-04 2011-05-26 グッドジーン インク． 核酸を安定的に保管する新規皮膚遺伝子カードとこれを用いた遺伝子分析方法、並びにこの応用方法
WO2009131733A1 (fr) 2008-04-21 2009-10-29 The Trustees Of Columbia University In The City Of New York Amplification de gab2 dans un mélanome
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
JP5568807B2 (ja) 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
US20110158953A1 (en) 2008-06-17 2011-06-30 University Of Rochester Tumor suppression through plexin c1
EP2151505A1 (fr) 2008-08-05 2010-02-10 Institut Gustave Roussy Procédé pour déterminer une prédisposition sur un carcinome de cellule basale et pour son criblage des traitements
WO2010025341A2 (fr) 2008-08-28 2010-03-04 Dermtech International Détermination de tranches d’âge d’échantillons cutanés
US20110262464A1 (en) 2008-10-03 2011-10-27 Danafarber Cancer Institute, Inc. Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Cancer Using GOLPH3
WO2010048431A2 (fr) 2008-10-22 2010-04-29 Reveal Sciences, Llc Dispositif, procédé et appareil pour analyser de la peau et des cheveux
EP3978928A1 (fr) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Méthodes diagnostiques et thérapeutiques se rapportant à des cellules souches cancéreuses
GB2512153B (en) 2008-11-17 2014-11-12 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
HU0900117D0 (en) 2009-02-26 2009-04-28 Genetic Immunity Kutatasi Topical or transdermal delivery kit
US20130143747A1 (en) 2011-12-05 2013-06-06 Myriad Genetics, Incorporated Methods of detecting cancer
US20110040571A1 (en) 2009-08-14 2011-02-17 Felicity Warren System and method for providing for teledermatology
WO2011039734A2 (fr) 2009-10-02 2011-04-07 Enzo Medico Utilisation de gènes impliqués dans l'indépendance d'ancrage pour l'optimisation du diagnostic et du traitement du cancer humain
JP2013507641A (ja) 2009-10-13 2013-03-04 ザ・ジョンズ・ホプキンス・ユニバーシティー 黒色腫腫瘍細胞の識別のためのバイオマーカー
GB0921329D0 (en) 2009-12-04 2010-01-20 Univ Surrey Biomarker
US20130079423A1 (en) 2010-02-24 2013-03-28 Myriad Genetics, Incorporated Diagnostic methods involving loss of heterozygosity
CA2791662A1 (fr) 2010-03-01 2011-09-09 Atsushi Terunuma Ensembles de genes pour detection d'exposition aux ultraviolets a et procedes d'utilisation associes
CN108535465A (zh) 2010-04-19 2018-09-14 生物标志物策略公司 预测药物敏感性、抗性和疾病进展的组合物和方法
GB201012590D0 (en) 2010-07-27 2010-09-08 Queen Mary & Westfield College Methods for diagnosing cancer
WO2012030840A2 (fr) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Signatures génétiques pour le diagnostic et le pronostic du cancer
WO2012031008A2 (fr) 2010-08-31 2012-03-08 The General Hospital Corporation Matières biologiques liées au cancer dans des microvésicules
US20130237445A1 (en) 2010-09-14 2013-09-12 The University Of North Carolina At Chapel Hill Methods and kits for detecting melanoma
WO2012040168A2 (fr) 2010-09-20 2012-03-29 Advanced Cell Diagnostics, Inc. Marqueurs biologiques permettant de différencier un mélanome d'un nævus bénin sur la peau
US20120201750A1 (en) 2010-09-20 2012-08-09 Bungwoo Ryu Serum biomarkers for melanoma metastasis
US20140141986A1 (en) 2011-02-22 2014-05-22 David Spetzler Circulating biomarkers
WO2012125411A1 (fr) 2011-03-11 2012-09-20 Metamark Genetics, Inc. Procédés de prédiction du pronostic dans le cancer
BR112013032232A2 (pt) 2011-06-16 2016-09-20 Caris Life Sciences Switzerland Holdings S A R L método de caracterização de câncer através do uso de biomarcador de ácido nucleico
EP2732052B1 (fr) 2011-07-15 2016-11-16 Leo Pharma A/S Profilage diagnostique de microarn dans le lymphome cutané à cellules t (ctcl)
BR112014002975A2 (pt) 2011-08-08 2017-03-01 Caris Life Sciences Luxembourg Holdings S A R L composições de biomarcador e métodos
EP2751570A4 (fr) 2011-08-31 2015-08-12 Oncocyte Corp Méthodes et compositions pour le traitement et le diagnostic du cancer
EP2758032B1 (fr) 2011-09-21 2021-10-27 Shiseido Americas Corporation Compositions et procédés pour traiter des affections de fonction de barrière cutanée compromise
EP2758536B1 (fr) 2011-09-23 2019-02-27 Galderma Research & Development Lignée cellulaire ptch1 de kératinocytes humains
US9926604B2 (en) 2011-10-14 2018-03-27 The Regents Of The University Of California Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
JP2014530836A (ja) 2011-10-19 2014-11-20 モルフォシス・アー・ゲー 炎症障害治療用のｉｌ１７ｃのアンタゴニスト
WO2013098797A2 (fr) 2011-12-31 2013-07-04 Kuriakose Moni Abraham Tests de diagnostic pour prédiction de pronostic, récurrence, résistance ou sensibilité à une thérapie et un état métastatique dans un cancer
JP6094481B2 (ja) 2012-05-02 2017-03-15 三菱レイヨン株式会社 皮膚に対する紫外線の影響を評価するためのプローブ又はプローブセット及び核酸マイクロアレイ
WO2013184905A1 (fr) 2012-06-06 2013-12-12 Myriad Genetics, Inc. Gènes du cancer héréditaires
CN116271053A (zh) 2012-08-13 2023-06-23 洛克菲勒大学 治疗和诊断黑素瘤
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
US9103749B2 (en) 2012-10-11 2015-08-11 Fast Forward Forensics, LLC Biological sample collection apparatus
US20160051493A1 (en) 2012-11-19 2016-02-25 The Trustees Of Columbia University In The City Of New York Methods of treatment of keratinocyte-derived lesions
TWI493169B (zh) 2013-01-18 2015-07-21 Univ Nat Cheng Kung 評估皮膚生理參數濃度及分布之光學系統及其方法
KR101832948B1 (ko) 2013-02-18 2018-02-28 듀크 유니버시티 신경교종 및 종양의 서브세트 내 tert 프로모터 돌연변이
WO2014130507A1 (fr) 2013-02-22 2014-08-28 Avery Dennison Corporation Adhésifs multicouche optiquement transparents, mousses, bandes de transfert et articles comprenant ces adhésifs
WO2014176446A1 (fr) 2013-04-26 2014-10-30 Dermtech International Biomarqueurs pour le diagnostic et le traitement de l'acne simple
US20150005184A1 (en) 2013-06-28 2015-01-01 Dermtech International Diagnosis of melanoma by nucleic acid analysis
WO2014208645A1 (fr) 2013-06-28 2014-12-31 中外製薬株式会社 Méthode de prédiction de la réponse d'un patient atteint d'une maladie prurigineuse à une thérapie avec antagoniste de l'il-31
US20150377751A1 (en) 2013-08-01 2015-12-31 The Procter & Gamble Company Method of collecting and quantifying melanin in skin
FR3011009B1 (fr) 2013-09-25 2016-11-25 Oreal Signature bacterienne de la dermatite atopique et son utilisation dans la prevention et/ou le traitement de cette pathologie
AU2014367369B2 (en) 2013-12-19 2020-03-26 Instytut Biologii Doswiadczalnej Im. M. Nenckiego Polskiej Akademii Nauk A method for detecting an increased risk of developing skin cancer and a use of a genotype variant of the GRHL3 gene
US20170115291A1 (en) 2014-05-28 2017-04-27 Dana-Farber Cancer Institute, Inc. Activating JAK Kinase Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
WO2016014705A1 (fr) 2014-07-22 2016-01-28 Dermtech International Caractérisation d'un mélanome à l'aide d'une signature moléculaire
CN106660176B (zh) 2014-08-27 2020-11-10 贺利氏德国有限两合公司 用于制造焊接接头的方法
US10709428B2 (en) 2015-05-01 2020-07-14 Dermtech, Inc. Non-invasive skin collection system
MX2018004400A (es) 2015-11-10 2018-05-11 Pathway Skin Inc Metodos y sistemas para mejorar la condicion dermica.
US10852307B2 (en) 2015-12-22 2020-12-01 National Jewish Health Methods of detecting and preventing atopic allergic diseases
JP6930992B2 (ja) 2016-02-29 2021-09-01 ファウンデーション・メディシン・インコーポレイテッド 腫瘍変異負荷を評価するための方法及びシステム
WO2017165199A1 (fr) 2016-03-25 2017-09-28 The Trustees Of Columbia University In The City Of New York Biomarqueurs de prochaine génération pour détecter un dommage causé par le soleil et prédire un risque de cancer de la peau
US20170329929A1 (en) 2016-05-11 2017-11-16 Sensus Healthcare Llc Virtual pathology for dermatology
CN106119242A (zh) 2016-06-24 2016-11-16 毕建红 一种基于自动化工作站的疑难微量法医物证dna提取试剂盒及其方法
WO2018011628A1 (fr) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Composés inhibiteurs thérapeutiques
WO2018065384A1 (fr) 2016-10-03 2018-04-12 Galderma Research & Development Profils d'expression de transporteurs abc et slc dans la peau, le foie et le rein d'êtres humains et de miniporcs
WO2018087155A1 (fr) 2016-11-09 2018-05-17 F. Hoffmann-La Roche Ag Instrument automatisé de dissection de tissu et procédés d'utilisation correspondants
US11441192B2 (en) 2016-11-15 2022-09-13 Quest Diagnostics Investments Llc Methods for detecting DNA mutations using mitra tip extraction
FR3060755A1 (fr) 2016-12-16 2018-06-22 L'oreal Methode de diagnostic d'une peau presentant des signes de secheresse
EP3589213A4 (fr) 2017-03-03 2021-03-31 Children's Hospital Medical Center Procédés non-invasifs de collecte et d'analyse de prélèvements de peau
CA3059425A1 (fr) 2017-04-10 2018-10-18 Dermtech, Inc. Procedes de detection non invasifs bases sur la peau
WO2019005764A1 (fr) 2017-06-27 2019-01-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Génotype du cmh-i limitant le paysage mutationnel oncogène
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
WO2019217478A1 (fr) 2018-05-09 2019-11-14 Dermtech, Inc. Nouveaux classificateurs de gènes et leurs utilisations dans des maladies auto-immunes
US20190369119A1 (en) 2018-06-04 2019-12-05 Avon Products, Inc. Protein Biomarkers for Identifying and Treating Aging Skin and Skin Conditions
GB201810897D0 (en) 2018-07-03 2018-08-15 Chronomics Ltd Phenotype prediction
GB2576374A (en) 2018-08-17 2020-02-19 Ecole Polytechnique Fed Lausanne Epfl Skin cell analysis
CN109785903A (zh) 2018-12-29 2019-05-21 哈尔滨工业大学（深圳） 一种基因表达数据分类器
EP3948290A4 (fr) 2019-03-26 2023-08-09 Dermtech, Inc. Nouveaux classificateurs de gènes et leurs utilisations pour des cancers de la peau
EP3947740A4 (fr) 2019-04-05 2022-12-21 Dermtech, Inc. Nouveaux classificateurs de gènes destinés à être utilisés dans la surveillance d'une lésion uv
US20210330245A1 (en) 2020-04-22 2021-10-28 Dermtech, Inc. Teledermatology system and methods
US20210345995A1 (en) 2020-05-08 2021-11-11 Dermtech, Inc. Automated sample scanning and segregation system and methods
CA3199922A1 (fr) 2020-11-24 2022-06-02 John Daniel Dobak Iii Evaluation de la charge mutationnelle dans la peau
WO2022187196A1 (fr) 2021-03-02 2022-09-09 Dermtech, Inc. Prédiction de la réponse thérapeutique
WO2022221326A1 (fr) 2021-04-13 2022-10-20 Dermtech, Inc. Classificateurs de gènes et leurs utilisations
IL309039A (en) 2021-06-04 2024-02-01 Dermtech Inc Sample collection system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
US20050221334A1 (en) * 2004-03-31 2005-10-06 Dermtech International Tape stripping methods for analysis of skin disease and pathological skin state
US20060040335A1 (en) * 2004-06-21 2006-02-23 Butt Tauseef R Diagnostic and screening methods and kits associated with proteolytic activity
WO2006002433A2 (fr) * 2004-06-24 2006-01-05 Veridex, Llc Procedes et reactifs pour la detection de melanome
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20070281314A1 (en) * 2006-04-20 2007-12-06 Dermtech International Methods for capture and detection of micro-RNA molecules from the skin by non-invasive tape stripping

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274908A1 (en) * 2007-05-04 2008-11-06 Dermtech International Diagnosis of melanoma by nucleic acid analysis
US10407729B2 (en) 2008-05-14 2019-09-10 Dermtech, Inc. Diagnosis of melanoma by nucleic acid analysis
US11753687B2 (en) 2008-05-14 2023-09-12 Dermtech, Inc. Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US11332795B2 (en) 2008-05-14 2022-05-17 Dermtech, Inc. Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US9057109B2 (en) 2008-05-14 2015-06-16 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US10072293B2 (en) 2011-03-31 2018-09-11 The Procter And Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
WO2013148806A1 (fr) * 2012-03-30 2013-10-03 The Procter & Gamble Company Procédé d'élaboration d'une architecture de données permettant d'identifier des agents agissant sur la pigmentation cutanée
US20130261024A1 (en) * 2012-03-30 2013-10-03 The Procter & Gamble Company System for Identifying Connections Between Perturbagens and Genes Associated with a Skin Hyperpigmentation Condition
WO2013148807A1 (fr) * 2012-03-30 2013-10-03 The Procter & Gamble Company Procédé de formulation d'une composition de blanchiment de la peau
WO2013148845A1 (fr) * 2012-03-30 2013-10-03 The Procter & Gamble Company Système d'identification de liens entre des perturbagènes et des gènes associés à une hyperpigmentation cutanée
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
US20150005184A1 (en) * 2013-06-28 2015-01-01 Dermtech International Diagnosis of melanoma by nucleic acid analysis
WO2014210467A1 (fr) * 2013-06-28 2014-12-31 Dermtech International Diagnostic de mélanome par analyse d'acide nucléique
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
US11578373B2 (en) 2019-03-26 2023-02-14 Dermtech, Inc. Gene classifiers and uses thereof in skin cancers
USD966300S1 (en) 2021-02-16 2022-10-11 Dermtech, Inc. Computer display panel with a graphical user interface for a dermatology report
USD966299S1 (en) 2021-02-16 2022-10-11 Dermtech, Inc. Computer display panel with a graphical user interface for a dermatology report
USD988399S1 (en) 2021-02-16 2023-06-06 Dermtech, Inc. Dermatology report document
USD989861S1 (en) 2021-02-16 2023-06-20 Dermtech, Inc. Dermatology report document

Also Published As

Publication number Publication date
WO2009140550A9 (fr) 2010-01-07
US11753687B2 (en) 2023-09-12
BRPI0913578A2 (pt) 2017-06-06
CA2724322C (fr) 2019-07-16
US9057109B2 (en) 2015-06-16
EP2626437A2 (fr) 2013-08-14
AU2009246180B2 (en) 2015-11-05
US20140256584A1 (en) 2014-09-11
US20210246514A1 (en) 2021-08-12
US20210222258A1 (en) 2021-07-22
WO2009140550A2 (fr) 2009-11-19
US20190367994A1 (en) 2019-12-05
CN102089444A (zh) 2011-06-08
US20210198749A1 (en) 2021-07-01
US11332795B2 (en) 2022-05-17
CA2724322A1 (fr) 2009-11-19
EP2294216A2 (fr) 2011-03-16
US20140154684A1 (en) 2014-06-05
AU2009246180A1 (en) 2009-11-19
JP2011520451A (ja) 2011-07-21
EP2626437A3 (fr) 2013-12-11
US10407729B2 (en) 2019-09-10
WO2009140550A3 (fr) 2010-02-25
US20150361509A1 (en) 2015-12-17
EP2294216A4 (fr) 2011-11-23

Similar Documents

Publication Publication Date Title
US11753687B2 (en) Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US20080274908A1 (en) Diagnosis of melanoma by nucleic acid analysis
AU2009285645B2 (en) Determining age ranges of skin samples
EP2333112A2 (fr) Pronostics de cancer du sein
US20150005184A1 (en) Diagnosis of melanoma by nucleic acid analysis
CA2556890A1 (fr) Pronostics de cancer du sein
US20150361500A1 (en) Biomarkers for diagnosis and treatment of acne vulgaris
JP2011509689A (ja) Ｉｉ及びｉｉｉ期結腸癌の分子病期分類並びに予後診断
US20180163276A1 (en) Method and apparatus for determining a probability of colorectal cancer in a subject
US20140100125A1 (en) Methods, Kits and Compositions for Determining Severity and Survival of Heart Failure in a Subject
US20150329911A1 (en) Nucleic acid biomarkers for prostate cancer
Class et al. Patent application title: DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY NUCLEIC ACID ANALYSIS Inventors: Sherman H. Chang (San Diego, CA, US) Sherman H. Chang (San Diego, CA, US)

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION